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CHAPTER 1 
MITOGEN ACTIVATED PROTEIN KINASES, MAP KINASE PHOSPHATASES 
AND CANCER 
Introduction 
 The tight regulation of signaling is an important mechanism that a cell employs to 
ensure that messages received both intra- and extracellularly are being interpreted 
appropriately, allowing the cell to respond to cues from its environment and make the 
changes necessary to continue to survive or to undergo cell death.  In cancer, disruption 
of normal cell signaling is critical to the continued growth and proliferation of tumor 
cells.  This can happen in a number of ways, including gaining the ability to sustain 
proliferative signaling as well as the ability to resist cell death.
1
  Sustained proliferative 
signaling often takes the form of increased growth factor activity.  This increase can 
contribute to the cell’s ability to resist cell death, but often the cell is also able to 
downregulate factors that would lead to apoptosis.  One group of signaling molecules 
with close ties to cancer that contains members involved in both cell growth and cell 
death is the Mitogen Activated Protein Kinase (MAPK) family. 
Mitogen Activated Protein Kinase Signaling: Overview 
 There are three major branches of MAPK signaling in mammalian cells: the 
extracellular signal regulated kinases (ERK), the c-Jun N-terminal kinases (JNK) and the 
p38 MAP Kinases (Fig. 1).  ERKs are activated by growth factors and generally 
contribute to cell growth.  JNK and the p38 MAP kinases can be activated by growth 
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factors, cytokines and cellular stress.  The JNK and p38 pathways can be involved in both 
cell growth and cell death, depending on the cellular context.
2-6
  All three branches follow 
a general signaling paradigm in which a stimulus is received at the cell membrane and is 
transmitted through upstream adaptor molecules and enzymes to a MAP kinase kinase 
kinase (MKKK).  ERK has only one MKKK, Raf.
2,6,7
  B-Raf has been shown to be the 
predominant isoform involved in activating MEK.
2
  JNK and p38 share several MKKKs, 
including ASK1 (Apoptosis Signal Regulating Kinase 1), MLK2 (Mixed Lineage Kinase 
2), MLK3 (Mixed Lineage Kinase 3), TAK1 (TGF-β-activating Kinase 1) and DLK 
(Dual Leucine Zipper Bearing Kinase).  Additional JNK MKKKs include MEKK1 (MEK 
Kinase 1), MEKK4 (MEK Kinase 4), MLK1 (Mixed Lineage Kinase 1), MLK4 (Mixed 
Lineage Kinase 4) and ZAK (Zipper Sterile- Motif Kinase).2,6,7  Phosphorylation of 
MKKK, in turn, allows for the phosphorylation of specific MAP kinase kinases (MKK).  
MEK activates ERK, MKK4/7 activates JNK and MKK3/6 activates p38.
2,6,7
  In order to 
be activated, each MAPK must be dually phosphorylated on threonine and tyrosine 
residues in a TXY motif.
5,6,8,9
  Once activated, the MAPKs go on to phosphorylate a wide 
variety of transcription factors, enabling them to affect the transcription of their 
respective target genes.
7
 
 There are multiple isoforms that make up each branch of the MAP Kinase family: 
six ERKs, three JNKs and four p38s.  The ERK branch is made up of ERK1-5 and 
ERK7/8.
2
  ERK1 and ERK2 are the best characterized and considered the “classical” 
members of the family.  These two kinases share an 83% sequence homology and are 
regulated by many of the same factors.
2
  The amino acid activation motif for ERK1 and 
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ERK2 is T-E-Y.  ERK3 and ERK4 are unique in that their activation motif is S-E-G, 
suggesting that these two kinases do not require dual phosphorylation for activation.  
Little else is known about either of these kinases.
2
  ERK5 has the same activation motif 
as ERK1 and ERK2 and has been shown to regulate cell survival and proliferation.
7
  
Along with ERK3 and ERK4, ERK7/8 is considered an atypical MAPK.  It has a T-E-Y 
activation motif similar to the conventional MAPKs, ERK1/2 and ERK5, but it is unique 
in that it has been shown to be constitutively phosphorylated, perhaps via 
autophosphorylation.
7
  There are three different JNK isoforms, JNK1, JNK2 and JNK3.  
These kinases have a T-P-Y activation motif.
2
  JNK1 and JNK2 are broadly expressed, 
with JNK3 displaying a more restricted tissue distribution.
7
  JNK1 and JNK2 are known 
to regulate the cell cycle via its phosphorylation of c-Jun, which forms part of the AP-1 
transcription factor.  These kinases also play an important role in regulating apoptosis in 
response to cell stress.
7
  The p38 branch of the MAP Kinase family has four members, 
p38α, p38β, p38γ and p38δ.  p38α is the predominant isoform.7  The activation motif for 
p38 is T-G-Y.  The p38 MAPKs are known to be strongly activated by cell stress and 
inflammatory cytokines and to negatively regulate the cell cycle.
7
  
MAP Kinase Phosphatases: Overview 
 Due to the wide ranging effects of MAP Kinase activation, it is important that 
there are mechanisms in place to attenuate their signals.  This is partially accomplished 
by a family of dual specificity phosphatases (DUSPs) called MAP kinase phosphatases 
(MKPs), which are the endogenous negative regulators of MAPKs (Fig. 1).   
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Figure 1. MAP kinase signaling. The three branches of the MAP kinase signaling 
family in mammalian cells are activated by stimuli at the cell surface. MAP kinase kinase 
kinases relay the signal to MAP kinase kinases, which activate ERK, JNK, and p38. The 
phosphorylation of their respective targets completes the cascade. MAP kinase 
phosphatases are endogenous negative regulators of MAP kinases. MKPs attenuate the 
signal by dephosphorylation and prevent MAPKs from carrying out their cellular 
functions
6
.  (Figure reproduced from Haagenson, K. K. & Wu, G. S. The role of MAP 
kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer 
Metastasis Rev 29, 143-149, (2010).) 
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MKPs are dual specificity threonine-tyrosine phosphatases that recognize the TXY motif 
present in the MAPKs.
8
  There are eleven MKP family members, which can be grouped 
by subcellular localization and substrate specificity (Table 1).  There are four nuclear 
MKPs: MKP-1 (DUSP1), MKP-2 (DUSP4), PAC-1 (Phosphatase of Activated Cells, 
DUSP2) and hVH3 (Human VH-1-like Clone 3, DUSP5).  MKP-1 has been reported to 
dephosphorylate ERK1/2, JNK1/2 and p38α10,11, but a subsequent study, in which MKP-
1 was conditionally expressed from the human metallothionein IIa promoter in U937 
cells, revealed a slightly more complex picture.  Conditional expression of MKP-1 
confirmed that the phosphatase could inhibit ERK, JNK and p38, but when MKP-1 levels 
were titrated, JNK and p38 were more sensitive to MKP-1 inhibition than ERK, 
suggesting that these MAPKs are the preferred substrates of MKP-1.
12
  MKP-2 has also 
been shown to dephosphorylate each of the three MAPKs at high concentrations, but 
when transfected into cells under conditions more closely resembling physiological levels 
it was shown to be active toward ERK and JNK, but showed little activity toward p38.
11
  
PAC-1 shows specificity for ERK and p38, while hVH3 is primarily an ERK specific 
phosphatase.
2,5,6,8
  A second group of MAPKs containing MKP-3 (DUSP6), MKP-4 
(DUSP9) and MKP-X, is found in the cytoplasm.  With the exception of MKP-4, which 
demonstrates activity toward both ERK and p38, this group exclusively targets 
ERKs.
2,5,6,8,13
  The third group of MKPs can claim MKP-5 (DUSP10), MKP-7 (DUSP 
16) and hVH5 (DUSP8) as its members and can be found in both the nucleus and the 
cytoplasm.  These three MKPs dephosphorylate JNK and p38.
2,5,6,8,13,14
  Although the 
MKPs might appear to be functionally redundant, they are known to display restricted  
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MKP (DUSP) 
Subcellular 
Location 
Substrate 
Specificity 
MKP-1 (DUSP-1) Nucleus JNK, p38 > ERK 
MKP-2 (DUSP-4) Nucleus ERK, JNK > p38 
MKP-3 (DUSP-6) Cytoplasm ERK 
MKP-4 (DUSP-9) Cytoplasm ERK, p38 
MKP-5 (DUSP-10) Nucleus/Cytoplasm JNK, p38 
MKP-7 (DUSP-16) Nucleus/Cytoplasm JNK, p38 
MKP-X (DUSP-7) Cytoplasm ERK 
PAC-1 (DUSP-2) Nucleus ERK, p38 
hVH3 (DUSP-5) Nucleus ERK 
hVH5 (DUSP-8) Nucleus/Cytoplasm JNK, p38 
 
Table 1.  MAP Kinase phosphatase family members.  The members of the MKP 
family, along with their subcellular localization and substrate specificity. 
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tissue expression.
2,8,14
   
The final member of the MKP family is MK-STYX, which is an inactive 
phosphatase.  It is grouped with the other MKPs based on structural similarity.
5
  The 
predominant features used to classify phosphatases as MKPs (Fig. 2) are the presence of 
a C-terminal catalytic domain and an N-terminal domain that contains two regions of 
sequence homology to the catalytic domain of the cdc25 phosphatase.
5,6,13,15
  Each of the 
MKPs has a kinase interaction motif between the two cdc25 homology domains.  MKP-1, 
hVH3 and MKP-7 also have nuclear localization sequences.  The three cytoplasmic 
MKPs, along with MKP-7 and hVH5, contain nuclear export sequences.  MKP-7 and 
hVH5 also have PEST domains.
13
  The active sites of the MKPs contain a catalytically 
critical cysteine residue present in a signature phosphatase motif: -HCXXXXXR-.  These 
residues work together with a conserved aspartate to facilitate the dephosphorylation of 
the MAPKs.
16
  A substrate induced activation model has been proposed for MKPs in 
which binding to the MAPK via a MAPK binding domain alters the interaction between 
the binding domain and the dual specificity phosphatase domain, which contains the 
active site.  This conformational change positions the catalytic domain for optimal 
dephosphorylation of the MAPKs
16
 and the structure/function relationship enables 
precise termination of MAPK signaling.  Thus, the interplay between MAPKs and MKPs 
helps to maintain the delicate balance of signals present in the cell and allows it to 
respond to changing environmental cues.  The inactivation of MKPs is not an area that 
has been widely studied.  It has been shown that MKP-1
17
 and MKP-2
18,19
 are able to be  
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Figure 2. Structural domains of the MKPs.  “Classification, domain structure 
and phylogenetic analysis of the dual-specificity MAPK phosphatases. (A) 
Domain structures of the ten catalytically active DUSP proteins and MK-STYX.  
In addition to the N-terminal non-catalytic domain containing the 
Cdc25/rhodanese-homology region and the catalytic site, the positions of the 
conserved kinase interaction motif (KIM), nuclear localization signals (NLS), 
nuclear export signals (NES) and PEST sequences are indicated.  The three 
subgroups revealed by the phylogenetic analysis are indicated by the background 
color. (B) DUSP sequence analysis. Human DUSP amino acid sequences were 
sligned using CLUSTALW and a phylogenetic tree was genereated. The three 
subgroups of DUSP proteins together with defining properties are indicated by 
the colored ovals.”  Figure reproduced with permission from Dickinson, RJ and 
Keyse, SM. J Cell Sci. 2006 Nov 15;119(Pt 22):4607-15. 
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degraded by the proteasome.  Proteasomal degradation of MKP-1 is enhanced by 
phosphorylation on Ser 296 and Ser 323.
20
  Conversely, phosphorylation of Ser 359 and 
Ser 364 protects MKP-1 from degradation.
17
  Similarly, phosphorylation of Ser 386 and 
Ser 391 of MKP-2 stabilizes the protein and protects it from proteasome-mediated 
degradation.
19
  In addition to degradation, it has been shown that reactive oxygen species 
are able to oxidize the cysteine residue in the catalytic site, leading to the inactivation of 
phosphatase activity.  This inactivation can either be reversible or irreversible, depending 
on how many oxygen molecules react with the cysteine residue.  Formation of sulfenic 
acid via the addition of one oxygen results in reversible inhibition of phosphatase 
activity, whereas as the formation of sulfinic (two oxygens) or sulfonic (three oxygens) 
acid resulted in irreversible inhibition of phosphatase activity.
21
 
MAP Kinases and Breast Cancer 
 In the United States, breast cancer is the most commonly diagnosed form of 
cancer in women (not counting skin malignancies), with an estimated 227,000 new cases 
in 2012.  Additionally, approximately 40,000 women are projected to die from their 
disease, making breast cancer the second-leading cause of cancer death among women 
behind lung cancer.
25
  Breast cancer is a heterogeneous disease made up of several 
different subtypes that have been identified through analysis of gene expression 
patterns.
26
   
The broadest classification of breast tumors is based on the expression of the 
estrogen receptor (ER), more specifically the expression of ER-.  Approximately 70% 
of human breast tumors are classified as positive for ER- expression.27,28  The ER is a 
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nuclear steroid hormone receptor whose structure is critical for understanding its 
function.  The N-terminal A/B domain contains activation function 1 (AF-1) which is 
responsible for the ligand independent activation of the receptor via protein-protein 
interactions and for the transcriptional activation of target genes.  The C domain is the ER 
DNA binding domain which is also involved in receptor dimerization.
29
  The D domain is 
a hinge region.  The E domain includes the ligand binding domain, which contains ligand 
dependent activation function 2 (AF-2).  In addition to ligand binding, this domain is 
involved in nuclear translocation, receptor dimerization and target gene expression.
29
  
The F domain is involved in the recruitment of co-activators.  When ligand binds to the 
receptor, helix 12, located in the E domain, moves over the ligand binding pocket and 
creates a surface for co-activator binding.  When the ER is bound to an antagonist, helix 
12 instead occupies a hydrophobic groove created by helices 3, 4 and 5.  This eliminates 
the ability of the receptor to interact with co-activators.
29
   
When ligand is bound to the receptor, the ER forms a dimer with another ER 
molecule and translocates to the nucleus where it is able to bind to DNA via estrogen 
response elements (EREs) present in the promoters of its target genes (Fig. 3).  The ERE 
consensus sequence is 5’-GGTCAnnnTGACC-3’.  Many genes regulated by estrogen, 
however, contain imperfect, non-palindromic ER binding sites.
30
  Additionally, it has 
been shown that an ER- dimer can bind to a half site if stabilized by protein-protein 
interactions with another transcription factor such as Sp-1.
30
  The ability of the ER to 
regulate transcription of its target genes by binding to consensus sequences and imperfect 
EREs, as well as its ability to interact with other transcription factors and co-activators 
11 
 
 
  
 
Figure 3.  Estrogen and Tamoxifen Mechanisms of Action.  Estrogen binding to the 
estrogen receptor causes its dimerization, which is followed by translocation to the 
nucleus and DNA binding, followed by the recruitment of co-activators and transcription 
of the target gene.  Tamoxifen competes with estrogen to bind to the receptor, preventing 
co-activator recruitment and transcription of target genes. 
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present in the cell, demonstrates that the context in which this signaling occurs is very 
important in determining its outcome.  Another example of how the context of cell 
signaling influences the transcription of estrogen regulated genes is through 
phosphorylation of the estrogen receptor.  These post-translational modifications are 
carried out by different kinases and modify ER activity.
27,29
  Several sites have been 
identified that can be phosphorylated by ERK, including Ser 102, Ser 104, Ser 106, Ser 
118, Ser 167 and Thr 311.
27
  Of these sites, phosphorylated Ser 104/106, Ser 118 and Ser 
167 have been suggested to have a connection to tamoxifen response in breast cancer. 
It has been shown that many breast cancers contain an increased proportion of 
cells with activated ERK.
22
  A 1997 study by Sivaraman et al. assessed the activity of 
ERK in 37 breast tissue samples, 11 of which were determined to be breast carcinomas.  
Each of the breast tumors showed increased ERK activity, measured by an in vitro kinase 
assay, compared to samples taken from patients with benign breast disease.  Subsequent 
analysis of the breast carcinomas showed that ERK mRNA expression was elevated in 
malignant epithelial cells, but not in stromal cells in both the primary tumors, as well as 
in lymph node metastases, suggesting that the overexpression and increased activity of 
ERK might play a role in tumor initiation and progression.
23
 
 Overexpression of both p38 and JNK1 has also been noted in primary breast 
tumors.  An examination of 14 breast tumor samples paired with non-malignant breast 
tissue samples from the same patients revealed that p38 expression and activity were both 
increased three-fold in the malignant tissues.  A similar three-fold increase in JNK 
expression was also observed.
24
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MAP Kinases and Endocrine Therapy Resistance 
 For women diagnosed with ER-positive breast cancer, first line therapy involves 
treatment with tamoxifen, a selective estrogen receptor modulator that mimics the 
binding of estrogen to the ER (Fig. 3).  In breast tissue, tamoxifen is known to act as an 
antagonist.  When tamoxifen is bound to ER, co-activators are unable to bind, repressing 
the transcription of estrogen responsive genes.  In bone and uterine tissue, however, 
tamoxifen has been shown to act as an agonist and has been associated with an increased 
risk of endometrial cancer.  This effect must be taken into consideration when using the 
drug in the clinic.  When used in an adjuvant setting, tamoxifen treatment reduces the 
odds of developing recurrent disease by approximately 40 to 50%.
31
  Approximately 30 
to 50% of patients presenting with metastatic disease will experience temporary 
remissions while on tamoxifen therapy.
31,32
  However, almost all of these women will go 
on to develop recurrent disease that is resistant to tamoxifen treatment.  This fact makes it 
clear that tamoxifen resistance is a major problem in the clinical setting and underscores 
the need to establish biomarkers to identify patients who will benefit the most from TAM 
therapy, as well as for development of novel drug targets. 
 Due to the heterogeneous nature of breast cancers and the complexity of signaling 
that occurs in tumors, it is not realistic to expect that a single mechanism would be 
identified as the cause of resistance in patients.  Therefore, it is important to continue to 
explore all possible causes in an attempt to determine which patients will experience the 
greatest benefit from tamoxifen treatment.  Even in the presence of tamoxifen, it is still 
possible to have activation of estrogen responsive genes (Fig. 4).  One such mechanism is 
14 
 
 
through the hypersensitization of the ER to ligand binding.  Following estrogen 
deprivation, the receptor is able to become activated in response to much lower 
concentrations of estrogen compared to conditions when ligand is present in abundance.  
Many molecular mechanisms of tamoxifen resistance have been suggested, including, but 
not limited to, several that involve MAP Kinase signaling.  In another scenario, 
tamoxifen is able to act as an agonist via ER interactions with transcription factors such 
as AP-1 or Sp-1.  For example, AP-1, which is a downstream target of MAPK signaling, 
binds to its response element and is able to crosstalk with the tamoxifen-bound ER, 
changing the context for the regulation of its target genes.  Yet another mechanism 
involves the ligand independent activation of the ER.  As noted earlier, ERK is able to 
directly phosphorylate several residues on the estrogen receptor.  Phosphorylation of Ser 
118, which is located in the ligand independent AF-1 portion of the ER A/B domain, is 
perhaps the best characterized, but most enigmatic of the sites targeted by ERK.  A 2006 
study done by Sarwar et al used immunohistochemistry to examine Ser 118 
phosphorylation in 301 breast tumor biopsies and found that 83% of the tumors that were 
positive for ER- were also positive for phospho-Ser 118.  Additionally, there was a 
correlation between positive Ser 118 phosphorylation and low tumor grade, indicating 
that phospho-Ser 118 might be associated with more favorable prognosis.
33
 When 
phosphorylation of Ser 118 was examined in a smaller group of patients (n=21) that 
15 
 
 
Figure 4.  Regulation of E2 responsive genes in the presence of tamoxifen.  Following 
estrogen deprivation, the estrogen receptor becomes responsive to lower concentrations 
of ligand than when ligand was plentiful.  This is called hypersensitization.  Ligand 
independent activation of the receptor can occur when kinases such as ERK 
phosphorylate residues in the ER, such as Ser 118, in AF-1 of the A/B domain.  
Tamoxifen bound ER binds to other transcription factors, like AP-1 or SP-1, using them 
as a scaffold to drive the transcription of  genes that were not previously transcriptionally 
regulated by ER. 
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had relapsed while on tamoxifen, a statistically significant difference in the levels of 
phospho-Ser 118 pre- and post-treatment was observed.  Eleven patients showed an 
increase in Ser 118 phosphorylation post-treatment.  In vitro studies, however, have 
shown increased phosphorylation of Ser 118 and ERK activity in tamoxifen resistant 
MCF7 cells, derived by long term culture in the presence of tamoxifen, compared to their 
tamoxifen sensitive MCF7 counterparts.
33
  The authors suggest that these results show 
that Ser 118 phosphorylation in breast tumors is not predictive of treatment failure as 
might be inferred from their in vitro results.  They do, however, acknowledge that the 
change in Ser 118 phosphorylation post-treatment might indicate a role in the emergence 
of resistance.
33
  It has also been demonstrated that ERK phosphorylation and its increased 
activity are associated with endocrine therapy resistance and decreased survival in breast 
cancer patients.
34
  Taken together these data seem to suggest that phosphorylation of Ser 
118 in the estrogen receptor is associated with favorable prognosis prior to tamoxifen 
treatment, but unfavorable prognosis after tamoxifen resistance is acquired.
35
 The other 
phosphorylation sites shown to be associated with tamoxifen response and targeted by 
ERK are Ser 104/106 and Ser 167.  Phosphorylation of Ser 104/106 leads to ligand 
independent activation of the receptor and agonistic activity of tamoxifen.
27
  
Phosphorylation of Ser 167 increases binding of the ER to DNA and enhances co-
activator binding in the presence of estrogen.  In vitro it has been shown that Ser 167 
phosphorylation reduces sensitivity to tamoxifen.
27
  However, similar to Ser 118 
phosphorylation, conflicting clinical data make it difficult to assess what the true 
contribution of this modification is to tamoxifen resistance.  In addition to 
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phosphorylation by ERK, Ser 167 is phosphorylated by Akt.  Akt activity has been 
associated with decreased overall survival in breast cancer.  In metastatic breast cancer, 
however, phospho-Ser 167 is associated with longer survival following relapse.
27
 
Overexpression of HER2, which has been shown to lead to the activation of ERK 
in breast tumor cell lines, has also been suggested as a mechanism of tamoxifen 
resistance in breast cancer.  It has been observed that tamoxifen treatment slightly 
increases the expression of both EGFR and HER2 and that the expression of these 
molecules was greatly elevated in resistant tumors.
36
  Clinical studies showed that 
patients whose tumors overexpress these two molecules were less likely to benefit from 
tamoxifen treatment.  A few different underlying mechanisms have been suggested for 
the contribution of EGFR and/or HER2 overexpression to tamoxifen resistance.
36
  In a 
study done by Massarweh et al, elevated levels of EGFR in MCF7 xenografts were 
associated with acquired tamoxifen resistance, but it was shown that genes classically 
regulated by estrogen were repressed in the presence of tamoxifen, suggesting that tumor 
growth in this model was through non-genomic ER-mediated activation of EGFR.  
Similar results were seen in tumors engineered to overexpress HER2.
36
  It is thought that 
this non-genomic activation might be carried out by a small fraction of ER that remains 
near the plasma membrane.
36
  Strong correlations amongst HER2, ERK and MKP-1 
protein expression have also been demonstrated.  Following activation of the MAPK 
pathway, it is thought that strong, sustained ERK activity leads to cell cycle arrest via 
senescence or differentiation. 
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Based on the hyperactivation of MAPK signaling in tamoxifen resistant tumors, it 
has been suggested that the inhibition of this pathway might restore tamoxifen sensitivity 
in breast cancer cells.  To this end, it has been shown that exogenous inhibitors of HER2 
signaling are able to partially restore sensitivity to anti-estrogens.  MCF7 cells engineered 
to overexpress HER2 were treated with AG1478.  This treatment abolished HER2 and 
MAPK phosphorylation, reduced ERE driven luciferase reporter activity in the presence 
of tamoxifen and showed inhibition of colony formation at levels similar to vector control 
treated cells, which was 80% compared to untreated controls.
37
  Another similar study 
done by Ghayad et al, showed that inhibition of the ERK pathway using the MEK 
inhibitor PD98059 and the PI3K/Akt pathway with the inhibitor LY294002 was able to 
restore tamoxifen sensitivity in cell line models of acquired tamoxifen resistance.  In their 
model of endocrine resistance, which was also initially derived from MCF7 cells, two 
independently selected clones developed concomitant activation of both the MAPK and 
PI3K/Akt pathways.  These clones also showed increased phosphorylation of Ser 118 and 
Ser 167 of the ER.  A combination treatment of tamoxifen and PD98059 completely 
reversed the tamoxifen resistant phenotype seen in these clones, shown by a reduction in 
BrdU incorporation and an increase in annexin V staining, which is an indicator of 
apoptosis, in comparison to vehicle treated control cells.  ER Ser 118 phosphorylation 
was also reduced.  Similar results were seen with the combination of tamoxifen and 
LY294002.  When the clones were subjected to treatment with combinations of 
PD98059, LY294002 and tamoxifen, interestingly, one clone was most sensitive to 
inhibition by tamoxifen and PD98059 and the other was most sensitive to tamoxifen and 
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LY294002.  The combination of all three drugs inhibited cell proliferation in a manner 
similar to the optimal inhibitor in each case.  Since these clones were selected through the 
same process, the authors suggest that this model reflects the heterogeneity observed in 
breast tumors and conclude that inhibiting both the MAP Kinase and PI3K/Akt pathways 
would be the most effective treatment strategy in a clinical setting.
38
 
 The previous data show that an increase in ERK signaling is a common event in 
breast cancer tamoxifen resistance and that inhibition of this pathway using small 
molecule inhibitors might be an effective approach to restore sensitivity.  This begs the 
question as to what role MAP Kinase phosphatases, the endogenous negative regulators 
of MAPKs, play in this process.  While very little is currently known about the 
connection between MKPs and tamoxifen response, MKP expression has been shown to 
be altered in a number of cancers and MKP-1 has been linked to resistance to a number 
of chemotherapeutic agents.  
MAP Kinase Phosphatases and Cancer 
 To date, six of the eleven MKP family members, MKP-1, MKP-2, MKP-3, MKP-
4, MKP-7 and PAC-1, have been shown to exhibit altered expression in a variety of 
human malignancies (Table 2).  Most of what is known pertains to MKP-1, since it is the 
founding member and best characterized of the MKP family, but to gain perspective on 
what is known about the overall picture of MKP signaling in cancer cells, it is important 
to briefly survey the contribution of the other MKPs to cancer development and 
progression. 
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Phosphatase Cancer Type Change in Expression 
MKP-1 
Bladder, Breast, Colon, Lung, 
Ovarian, Prostate 
Downregulated in Bladder (M) 
Upregulated in Breast (M, P) 
Downregulated in Colon (M) 
Upregulated in Lung (M, P) 
Upregulated in Ovarian (M, P) 
Downregulated in Prostate (M, P) 
MKP-2 
Breast, Liver, Ovarian, Pancreatic, 
Glioma 
Upregulated in Breast (P) 
Upregulated in Liver (M) 
Downregulated in Ovarian (M) 
Upregulated in Pancreatic (P) 
Downregulated in Glioma (M) 
MKP-3 Breast, Ovarian, Pancreatic 
Upregulated in Breast (M) 
Downregulated in Ovarian (M, P) 
Downregulated in  Pancreatic (M, P) 
MKP-4 Skin Downregulated (M, P) 
MKP-7 Leukemia Downregulated (M) 
PAC-1 Ovarian Upregulated (M) 
 
Table 2.  Alterations of MKP Expression in Human Cancer.  M=change in mRNA 
expression.  P=change in protein expression.  References: MKP-1
3,4,8,9,14,24,39-42
, MKP-
2
9,24,43-45
, MKP-3
9,46-49
, MKP-4
50
, MKP-7
51,52
, PAC-1
53
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PAC-1, MKP-3, MKP-4, and MKP-7 and Cancer 
 PAC-1, MKP-3, MKP-4 and MKP-7 have been shown to play a role in various 
cancer types.  PAC-1, a nuclear phosphatase with activity directed toward ERK and p38, 
has been shown to be associated with overall survival in ovarian cancer.  In a study of 
thirty-nine patient samples from serous ovarian tumors, high PAC-1 mRNA expression 
levels correlated with worse overall survival compared with those patients whose tumors 
expressed low PAC-1 levels.
5,53
  MKP-3, a cytoplasmic, ERK specific phosphatase, is 
connected to pancreatic, ovarian and breast cancer.  The loss of MKP-3 expression in 
pancreatic cancer is associated with disease progression.  Compared to in situ 
carcinomas, a decrease in expression was observed in primary invasive pancreatic tumor 
tissues
46
.  Another study revealed that many precursor lesions lacking MKP-3 expression 
harbored K-ras mutations.
5,47
  Similar losses of expression have been observed in ovarian 
cancer cell lines.  MKP-3 protein expression was shown to be much lower in these cell 
lines compared to normal samples and immortalized cell lines.
5,49
  MKP-4 is an ERK and 
p38 specific phosphatase located in the cytoplasm.  Loss of MKP-4 expression has been 
connected to skin cancer development.  Reintroduction of MKP-4 in malignant cells led 
to microtubule disruption and in vivo tumor suppression.
5,50
  MKP-7, a JNK and p38 
phosphatase found in both the nucleus and the cytoplasm, has been associated with 
leukemia.  Overexpression of MKP-7 in Rat-1 fibroblasts transformed with BCR-ABL 
showed a reduction in JNK activation and a decreased ability to be transformed both in 
vitro and in vivo.
5,52
  Additionally, downregulation of MKP-7 by miR-24, whose 
expression is induced by both AML-1 and AML1-ETO, has been linked to development 
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of acute myeloid leukemia.  Decreased MKP-7 led to increased phosphorylation of JNK 
and p38, which stimulated myeloid cell growth and inhibited differentiation.
5,51
 
MKP-2 and Cancer 
 MKP-2, which is a nuclear phosphatase that primarily targets ERK and JNK, has 
shown altered expression in liver, pancreatic, ovarian and breast cancers.  MKP-2 was 
first identified by Misra-Press et al in 1994.
54
  The authors of this study demonstrated that 
MKP-2 is expressed in a wide variety of rat tissues in a profile that is overlapping yet 
distinct from MKP-1.  They also suggested that this differential expression combined 
with the unique N-terminal sequences of the two phosphatases indicate distinct functional 
roles for each protein.
54
  In a study that investigated hepatocarcinogenesis and hepatoma, 
no expression of MKP-2 could be detected in normal liver, but was present in three out of 
five primary hepatomas studied.
5,43
  MKP-2 mRNA levels were also elevated in ascites 
hepatoma cell lines compared to normal liver.
5,43
  The authors of this study suggest that 
MKP-2 expression might be used as a tumor marker in the liver.
5,43
  MKP-2 has also been 
linked to the suppression of ERK activity in pancreatic cancer cells harboring K-ras 
mutations.
44
  The expression of MKP-2 in pancreatic tumor cell lines correlated with 
MEK expression.  When BxPC-3 and Capan-1 cells were treated with MEK inhibitor 
PD98059, MKP-2 expression was markedly decreased.
5,44
  Subsequent work examining 
post-translational modifications of MKP-2 showed that ERK is able to phosphorylate 
MKP-2 on Ser 386 and Ser 391, which stabilizes the protein and forms a feedback loop 
for the regulation of ERK signaling.  Inhibition of ERK activity with MEK inhibitor 
U0126 abolished MKP-2 phosphorylation and co-treatment with the proteasome inhibitor 
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MG132 showed that in the absence of this phosphorylation, MKP-2 protein is degraded 
by the proteasome.
19
  Additionally, MKP-2 has been shown to be overexpressed in serous 
borderline tumors of the ovary, but expression was lost in serous carcinomas.
9
  MKP-2 is 
co-expressed with MKP-1 in breast cancer.
24
 
MKP-1 and Cancer 
 MKP-1 is a nuclear phosphatase that is able to dephosphorylate all three MAPKs, 
with preference for JNK and p38 as substrates compared to ERK.  It is unclear what the 
precise physiological function of MKP-1 is in normal tissues, as MKP-1 knockout mice 
show no obvious phenotype.
2
  Other studies seem to indicate, however, that MKP-1 may 
be involved in the inhibition of pro-inflammatory signaling.
13
  MKP-1 has also been 
identified as a transcriptional target of p53, suggesting it may play a role in cell cycle 
control.
55
  The second intron of MKP-1 contains a p53 binding site.  This study also 
showed that when MKP-1 phosphatase activity was inhibited using vanadate, a general 
phosphatase inhibitor, induction of p53-mediated G1 arrest in response to growth factor 
stimuli was compromised.  p53 also regulates MKP-1 protein expression in response to 
oxidative stress in colon cancer cells.
56
  In addition to colon cancer, MKP-1 expression 
has been shown to be altered in prostate, bladder, ovarian, non-small cell lung and breast 
cancers.
5,6,8
  In colon, bladder and prostate cancer, MKP-1 is overexpressed in the early 
stages of disease, but expression seems to be lost as the disease progresses.
5,9
  Microarray 
analysis of colorectal tumor samples from nine patients participating in a Phase I/II 
clinical trial examining a treatment regimen consisting of bevacizumab, a VEGF 
inhibitor, and radiation therapy revealed that MKP-1 mRNA expression was significantly 
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downregulated in all samples after treatment.  The size of decrease, however, varied from 
patient to patient.
5,40
  The authors suggest that this decrease is due to the reduction in 
tumor proliferation following treatment.
40
  MKP-1 expression has been linked to clinical 
outcome in ovarian cancer, where increased expression correlated with shorter 
progression-free survival.
5,9
  In a separate study, moderate to strong MKP-1 expression 
was seen in 57.6% of invasive primary ovarian tumors (n=66).
5,41
  In lung cancer, when 
compared to normal tissue samples, MKP-1 expression was increased in non-small cell 
lung cancer tissue samples.  In this study, high MKP-1 expression levels independently 
predicted better survival outcomes.
8
  In a small clinical study, tumor samples were 
obtained from 14 breast cancer patients and examined for expression of the three 
MAPKs.  This study showed that ERK, JNK and p38 were all upregulated in malignant 
versus non-malignant tissue samples.  The study also looked at JNK activity and found 
that it was 30% lower in malignant tissue than in normal tissue.  Further investigation 
into the disparity between higher protein expression level and reduced activity level of 
JNK revealed that MKP-1, along with MKP-2, displayed increased expression in the 
malignant tissue.  The authors suggest this increase in MKP expression as a possible 
mechanism for the decrease in JNK activity.
5,24
  Since a reduction in JNK activity may 
play a role in reducing the effectiveness of chemotherapy drugs, it is possible that 
downregulating MKP-1 expression might be a novel way to combat chemotherapy 
resistance.
5
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MKP-3, MKP-1 and Breast Cancer Treatment Resistance 
MKP-3 and Tamoxifen Resistance 
 MKP-3 is the only MKP so far to be directly studied in relation to tamoxifen 
resistance in breast cancer.  A study done by Cui et al analyzed MKP-3 mRNA 
expression in nine tumors, four of which were tamoxifen sensitive and five that were 
resistant to tamoxifen treatment.  Their results showed that MKP-3 mRNA expression 
was increased 2.5 times in resistant tumors compared to sensitive ones.  They then used 
an in vitro model of tamoxifen resistance.  MCF7 and T47D cells were cultured long term 
(over six months) in the presence of tamoxifen and used to confirm that MKP-3 mRNA 
was increased in these cells compared to their tamoxifen sensitive counterparts.  Using 
MCF7 cells engineered to overexpress MKP-3, they next tested the effect of this 
overexpression on tamoxifen sensitivity.  They showed that MCF7 vector control cells 
exhibited increased colony forming ability in the presence of estrogen and that this 
increase was blocked following tamoxifen treatment.  MKP-3 overexpression cells 
treated with estrogen exhibited a similar colony forming ability to vector control cells 
treated with estrogen, but when these cells were treated with tamoxifen they showed a 
ten-fold increase in colony formation compared to vector control cells under the same 
conditions.  Western blot analysis showed that MKP-3 overexpression cells treated with 
tamoxifen had the highest level of activated ERK compared to vehicle or estrogen treated 
MKP-3 overexpressing cells.  To explain these seemingly paradoxical results, the authors 
suggested that breast tumors might upregulate phosphatase expression to compensate for 
chronic activation of ERK signaling.  They hypothesize that tamoxifen resistance 
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emerges due to inactivation of MKP-3 phosphatase activity by ROS and that this loss of 
activity disrupts the compensatory MAPK regulatory loop seen in breast tumors.
48
 
 In addition to tamoxifen resistance, MKP-3 has also been implicated in cisplatin 
resistance in ovarian cancer.  As mentioned previously, MKP-3 protein expression was 
decreased in tumor tissue samples and ovarian cancer cell lines compared to normal 
samples and immortalized, non-tumorigenic cell lines.  Exogenous expression of MKP-3 
in A2780cp cells, which are cisplatin resistant, increased their sensitivity to cisplatin 
treatment up to 2.5-fold when compared to vector control cells.
5,49
 
MKP-1 and Chemotherapy Resistance 
 Growing evidence suggests that MKP-1 may play a role in chemotherapy 
resistance (Fig. 5).
6
  In human lung cancer cell lines, overexpression of MKP-1 protected 
them from cisplatin-induced death.
6,39
  It was shown that MKP-1 targets JNK in response 
to cisplatin, leading to increased c-Jun activity and that MKP-1
-/-
 mouse embryo 
fibroblasts (MEFs) were more sensitive to cisplatin and etoposide than MKP-1
+/+
 MEF 
cells.  This study also demonstrated that activation of JNK is required for sensitizing cells 
to cisplatin.
6,39
  It has also been shown that induction of MKP-1 after treatment with 
cisplatin is a general event in ovarian cancer cell lines, with knockdown of MKP-1 by 
siRNA increasing cisplatin induced, JNK-mediated cell death.
3,6
   
While MKP-1 has not yet been linked to tamoxifen resistance, it has been well-
studied in connection with resistance to many other chemotherapeutic agents in breast 
cancer.  Overexpression of MKP-1 was able to protect breast cancer cells from 
chemotherapy-mediated apoptosis when they were treated with doxorubicin, 
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mechlorethamine and paclitaxel.
6,57
  This is significant because many chemotherapy 
drugs, including anthracyclines, alkylating agents and taxanes, use JNK activation to 
carry out their anticancer activity.
4,6,57
  A study in NSCLC looked at the effect of the 
EGFR tyrosine kinase inhibitor AG1478 on JNK signaling.  The results showed that 
following treatment of PC-9 cells, MKP-1 expression was reduced.  Ectopic 
overexpression of MKP-1 reduced JNK activation and decreased AG1478-induced 
apoptosis.
58
  These results indicate that AG1478 also uses JNK activation as a mechanism 
for apoptosis induction.  Treatment of breast cancer cell lines with anthracyclines resulted 
in the repression of MKP-1 and increased phosphorylation of ERK.
59
  Further silencing 
of MKP-1 with siRNA resulted in decreased ERK activation, but the mechanism for this 
remains unclear.
6,59
  A similar study looked at MKP-1 overexpression following 
treatment with doxorubicin in a panel of breast cell lines.
6,60
  Results showed that 
doxorubicin treatment decreased MKP-1 protein expression and that this decrease 
preceded an increase in active ERK and JNK.  MKP-1 staining was done in 30 complete 
tissue sections that included histologic normal breast (n=30), as well as hyperplastic 
(n=11), in situ (n=18) or infiltrating carcinomas (n=30) within the same tissue section.  
MKP-1 was overexpressed in all in situ carcinomas and in 50% of infiltrating 
carcinomas.  This study also further characterized the effect of doxorubicin treatment ex 
vivo in 50 patient samples, 27 of which did not show overexpression of MKP-1 and 23 of 
which did.  MKP-1 expression was decreased following doxorubicin in 39 samples, while 
the other 11 samples showed a modest increase in MKP-1 levels.  ERK and JNK 
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Figure 5.  MKP-1 and chemoresistance.  Overexpression of MKP-1 plays a role in the 
development of resistance to chemotherapy in breast, lung and ovarian cancers.  In breast 
cancer, decreased JNK and p38 activity contributes to resistance to oxidative stress 
induced death.  Treatment with proteasome inhibitors increases ERK and decreases JNK 
activity, leading to proteasome inhibitor resistance because of decreased levels of 
apoptosis.  Activation of the glucocorticoid receptor increases MKP-1 mRNA  and leads 
to decreased JNK and ERK activity, which factors in to paclitaxel resistance.  Cisplatin 
resistance in lung and ovarian cancer is caused in part by decreased JNK activity.  (Figure 
reproduced from Haagenson, K. K. & Wu, G. S. The role of MAP kinases and MAP 
kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 29, 
143-149, (2010).) 
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activation increased following the downregulation of MKP-1, mirroring the results seen 
in tumor cells.  Additionally, in a series of 96 patients, it was shown that following 
surgery and systemic treatment with chemotherapy, anti-hormonal therapy or both, those 
who harbored MKP-1 overexpression were more likely to experience relapse than those 
who did not, suggesting that MKP-1 might be a novel drug target in breast cancer.
60
 
Proteasome inhibition has been linked to the induction of MKP-1 expression.
6,61
  
This resulted in a decrease in ERK signaling and further blockade of ERK led to an 
increase in proteasome inhibitor mediated apoptosis.
6,61
  This induction of MKP-1, 
however, is thought to also limit the efficacy of proteasome inhibitors because of a 
subsequent decrease in JNK activity, resulting in decreased levels of apoptosis.
6,62
  
Knockdown of MKP-1 resulted in increased proteasome inhibitor sensitivity.
6,62
  
Interestingly, evaluation of a combination treatment with proteasome inhibitors and 
doxorubicin, which is known to decrease MKP-1 levels in breast cancer, showed 
increased apoptosis, decreased MKP-1 levels and increased JNK phosphorylation in vitro 
and resulting in delayed tumor growth in an in vivo xenograft model.
6,62
  Similar to the 
combination of proteasome inhibitor treatment and doxorubicin, a combination of 
proteasome inhibitor treatment and p38 blockade also inhibited MKP-1 expression, 
increased JNK activity and increased apoptosis in the A1N4-myc and BT474 breast 
cancer cell lines.
6,63
 
Activation of the glucocorticoid receptor following treatment with dexamethasone 
can also inhibit paclitaxel induced apoptosis by preventing the induction of ERK and 
JNK activation.
6,64
  Activation of the glucocorticoid receptor has been shown to lead to 
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an increase in MKP-1 mRNA, which could be an underlying mechanism for the decrease 
in ERK and JNK activation. Using siRNA directed at MKP-1 decreased the anti-
apoptotic activity of glucocorticoids.
6,64
 
Inhibition of JNK and p38 signaling by overexpression of MKP-1 also increased 
resistance to H2O2-induced death in MCF7 breast cancer cells, with a correlation between 
MKP-1 induction and the disappearance of phosphorylated MAPKs, suggesting that 
MKP-1 might play a physiologic role in the inactivation of oxidative damage induced 
MAPK activities.  Furthermore, loss of MKP-1 sensitized cells to oxidative damage 
induced death.
4,6
 
Conclusion 
 These results show that, in general, overexpression of MKP-1 seems to contribute 
to chemotherapy resistance in breast cancer, but MKP-1 involvement in tamoxifen 
sensitivity has yet to be characterized.  Taking into consideration that MKP-1 
phosphatase activity is preferentially directed toward JNK and p38 rather than ERK, this 
suggests that increases in MKP-1 expression might contribute to changes in tamoxifen 
sensitivity via the inhibition of JNK-mediated apoptosis.  MKP-2, which can 
dephosphorylate all three MAPKs, but preferentially inactivates ERK and JNK, has also 
been shown to be overexpressed in breast cancers.  Both MKP-1 and MKP-2 proteins 
have been shown to be stabilized following phosphorylation by ERK, forming a feedback 
loop.  The activation of the ERK pathway in tamoxifen resistant breast cancers is well 
documented and has been connected to poor prognosis in patients.  Taken together, these 
data suggest that further investigation of the connection among MKPs, MAPK signaling 
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and tamoxifen resistance is warranted, leading to the hypothesis that increases in MKP 
expression are associated with changes in tamoxifen sensitivity.  Investigating MKPs and 
their regulation of MAP Kinases in breast cancer is important because tamoxifen 
resistance is a major clinical problem and MAPK signaling has been implicated in its 
development.  In the research presented in this dissertation, the characterization of MKP-
1 and MKP-2 expression in breast cancer cells will form the knowledge base necessary to 
begin to dissect their contributions to tamoxifen sensitivity.  Investigating changes in 
MAP Kinase activation and correlating them to MKP expression in both tamoxifen 
sensitive and tamoxifen resistant cells will clarify the overall picture of MAPK signaling 
in tamoxifen sensitivity and finally, examining the promoter sequence features of MKPs 
will provide insight into their regulation in the context of breast cancer. 
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CHAPTER 2 
CHARACTERIZATION OF MKP-1 IN BREAST CANCER TAMOXIFEN 
SENSITIVITY 
Introduction 
MKP-1 is the founding member of the MAP Kinase Phosphatase family.  It has 
the ability to dephosphorylate all three MAPKs, however at physiological levels seems to 
preferentially inactivate JNK and p38.
12
  It is unclear what the precise physiological 
function of MKP-1 is in normal tissues, as MKP-1 knockout mice show no obvious 
phenotype.
2
  Other studies seem to indicate, however, that MKP-1 may be involved in the 
inhibition of pro-inflammatory signaling.
13
    In vascular smooth muscle cells, MKP-1 is 
activated by mechanical stress and seems to inhibit the proliferation of these cells through 
MAPK dephosphorylation.   MKP-1 has also been identified as a transcriptional target of 
p53, suggesting it may play a role in cell cycle control.
55
  The second intron of MKP-1 
contains a p53 binding site.  This study also showed that when MKP-1 phosphatase 
activity was inhibited using vanadate, a general phosphatase inhibitor, induction of p53-
mediated G1 arrest in response to growth factor stimuli was compromised.  p53 also 
regulates MKP-1 protein expression in response to oxidative stress in colon cancer 
cells.
56
 
Changes in MKP-1 expression in several cancer types have been shown to lead to 
changes in metastatic potential and time to progression.  In non-small cell lung cancer 
(NSCLC), knockdown of MKP-1 by siRNA reduced the invasive ability  and angiogenic 
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potential of H460 cells and decreased tumorigenicity and metastasis  in in vivo mouse 
models.
65
  In colorectal cancer, MKP-1 expression in human tumor samples from patients 
treated with cetuximab, a monoclonal antibody toward EGFR, was assessed in 
conjunction with KRAS and BRAF mutational status.  The results showed that patients 
with wild-type KRAS and BRAF that overexpressed MKP-1 had a significantly shorter 
time to progression than those that did not overexpress MKP-1.
66
 
  Particularly relevant to the studies presented here, MKP-1 has been shown to be 
overexpressed in breast cancer
24
 and overexpression in other cancer types has been linked 
to tumor progression, which suggests that inhibiting MKP-1 activity might be a strategy 
to employ in the treatment of breast cancer.  To this end, studies have been done to try to 
identify small molecule inhibitors of MKP-1 from a pyrrole carboxamide library of 
compounds.
67,68
  Structural analogs of the lead compound SID 3717140 were developed 
in an attempt to identify MKP-1 inhibitors with improved potency, activity and 
selectivity.
67
  A separate study using a pyrrole carboxamide library identified two 
compounds, PSI2106 and MDF2085, which were determined to be potent and selective in 
chemical screens, but their biological activity was not as good as expected.
68
  Subsequent 
work in this area identified a cell active compound, NSC 95397, using a fluorescence 
based chemical complementation assay.
69
  This compound was able to reverse 
dexamethasone protection in paclitaxel treated cells.  Combination treatment of NSC 
95397 and paclitaxel in the absence of dexamethasone proved to be antagonistic, but in 
the presence of dexamethasone, the effect of their combination was synergistic.  These 
results suggest that inhibition of MKP-1 occurred only in conditions of MKP-1 
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upregulation.
69
  These data indicate that a considerable amount of effort is still needed to 
discover small molecules capable of effectively inhibiting MKP-1.  Success in this area 
would be beneficial to dissecting the precise role of MKP-1 in the inhibition of 
inflammatory signaling as well as its connection to tumor progression and chemotherapy 
resistance. 
In breast cancer, women who present with estrogen receptor positive disease are 
treated with tamoxifen and it is well known that the development of recurrent, tamoxifen 
resistant disease is a major problem in the clinical setting.  MKP-1 has been connected to 
chemotherapy resistance in lung, ovarian and breast cancers
6
.  Thus far, no connection 
has been made between MKP-1 and response to tamoxifen, but its history of being 
involved in chemotherapy resistance suggests that the potential for a link between the two 
be investigated further.  In order to fully explore this possibility, this work will set out to 
identify a cell line model appropriate to study the role of MKP-1 in tamoxifen sensitivity, 
examine the response of MKP-1 protein expression following treatment with estrogen 
and tamoxifen and determine if overexpression of MKP-1 contributes to changes in 
tamoxifen sensitivity in breast cancer cells.  These studies will form the foundation of 
investigating the hypothesis that increases in MKP-1 expression are associated with 
changes in tamoxifen sensitivity in breast cancer. 
Materials and Methods 
Cell Lines and Culture Conditions 
MDA-MB-231
70
, T47D, CAOV3-pLKO.1 and CAOV3-shMKP1 cells were 
cultured in Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% 
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fetal bovine serum (FBS).  MCF10A cells were maintained in DMEM/F12 (1:1) medium 
supplemented with 5% FBS, 10 µg/mL insulin, 20 ng/mL epidermal growth factor, 100 
ng/mL cholera enterotoxin and 0.5 µg/mL hydrocortisone.
71
  MCF7 cells were 
maintained in DMEM/F12 (1:1) medium supplemented with 5% FBS, 10 µg/mL insulin 
and 0.5 nM estrogen.
72
  MCF7 tamoxifen resistant cells (MCF7-TAMR) cells were 
generated in the lab of Dr. Malathy Shekhar by gradual exposure to increasing 
concentrations of 4-OH-tamoxifen over a period of six months. (Gerard and Shekhar, 
manuscript in preparation.)  MCF7-TAMR cells are able to tolerate exposure of up to 10 
µM TAM.  These cells were routinely maintained in DMEM/F12 (1:1) medium 
supplemented with 5% FBS, 10 µg/mL insulin and 1 µM tamoxifen.  MCF7 cells stably 
expressing empty vector (pEGFP or pCDNA3.1) and MKP-1
4
 or MKP-2
19
 were 
maintained in the same medium as MCF7 cells and stable clones were selected with 500 
µg/mL G418.  All cell lines were maintained in a 37°C incubator with a humidified 
atmosphere consisting of 5% CO2.  For experiments involving treatment with estrogen, 
tamoxifen (TAM) or ICI 182,780 (ICI), cells were depleted of hormones by culturing in 
phenol red free media supplemented with charcoal-stripped FBS and 10 µg/mL insulin. 
Reagents 
17-β-estradiol, G418 antibiotic and 4-OH tamoxifen were purchased from Sigma.  
ICI 182,170 was purchased from Tocris.  Human recombinant insulin was purchased 
from GIBCO.  Anisomycin (Sigma) was a gift from Dr. Raymond Mattingly. 
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Whole Cell Lysates 
To prepare whole cell lysates, cells were trypsinized with .05% Trypsin-EDTA 
(GIBCO) and counted using a hemocytometer.  3 x 10
5
 to 5 x 10
5
 cells were plated in 60 
mm dishes and allowed to adhere overnight.  Treatments were added the following 
morning.  At the end of the treatment period, medium was removed and cells were 
washed with ice cold phosphate-buffered saline (PBS).  Following the removal of PBS, 
cells were lysed with NP-40 lysis buffer (150mM NaCl, 1% NP40, 50 mM Tris-Cl) 
containing a Complete Mini Protease Inhibitor Cocktail tablet (Roche Diagnostics).  Cells 
were detached by scraping and incubated on ice for one hour to ensure complete lysis, 
then centrifuged at 14,000 rpm for ten minutes at 4°C to clear cell debris.  Protein 
concentration was determined using the Bio-Rad protein assay and absorbance was 
measured at 595nm with a Genesys 10UV spectrophotometer (Spectronic Unicam).  2X 
Laemmli’s sample buffer was added in equal volume to the lysates which were then 
boiled for five minutes. 
Western Blot Analysis 
 Steady state levels of protein expression were measured by western blot analysis.  
Whole cell lysates were electrophoresed through a 12% polyacrylamide gel.  Proteins 
were transferred to a polyvinylidene diflouride membrane (Millipore) using a semi-dry 
transfer method.  Membranes were blocked for thirty minutes in either 10% milk (ECL 
Plus detection), 5% bovine serum albumin (ECL Plus detection) or 0.1% casein in 0.2X 
PBS (Odyssey detection) according to antibody specifications.  Membranes were 
incubated in primary antibody overnight at 4°C, washed for ten minutes three times in 
37 
 
 
either TBST (Tris-buffered saline with Tween 20; for detection with ECL Plus) or PBST 
(Phosphate-buffered saline with Tween 20; for detection with Odyssey) and then 
incubated with secondary antibody for one to two hours.  Proteins were detected using 
either the Amersham ECL Plus Western Blotting Detection Reagents Kit (GE 
Healthcare) or the Odyssey Infrared imaging system according to the manufacturer’s 
protocol. 
Antibodies 
MKP-1 (C-19) antibody and Estrogen Receptor  HC-20 antibody were 
purchased from Santa Cruz Biotechnology.  PhosphoPlus SAPK/JNK (Thr183/Tyr185) 
Antibody Kit, PhosphoPlus p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) Antibody Kit, 
Phospho-Estrogen Receptor  (Ser118) (16J4) antibody, GAPDH (D16H11) XP 
monoclonal antibody, goat-anti-mouse-HRP and goat-anti-rabbit-HRP secondary 
antibodies were purchased from Cell Signaling Technology.  Anti-V5 antibody was 
purchased from Invitrogen.  Anti--actin antibody was purchased from Sigma Aldrich.  
When using the Odyssey scanner, Alexa-Fluor 680 conjugated to goat-anti-rabbit or goat-
anti-mouse (Invitrogen) or IRDye 800 conjugated to goat-anti-rabbit or goat-anti-mouse 
(Li-Cor) were used as secondary antibodies.  
RNA Isolation and cDNA Synthesis 
1.0x10
6
 cells were seeded in 10 cm dishes.  Cells were lysed using TRIzol 
Reagent (Life Technologies) according to the manufacturer’s protocol to isolate total 
RNA.  RNA was quantified using the Genesys UV10 spectrophotometer (Spectronic 
Unicam).  Absorbance was measured at 260 and 280 nm and RNA concentration in µg/ul 
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was calculated using the following formula: (OD260 x 100 x 40)/1000.  cDNA was 
generated using the SuperScript III Reverse Transcriptase kit (Invitrogen) using 5 µg 
total RNA as a template and random primers.  All other steps were carried out according 
to the manufacturer’s protocol.  Samples were incubated in the PTC-200 Peltier thermal 
cycler. 
Real Time RT-PCR 
Samples were tested in either duplicate or triplicate.  Reactions were carried out 
using the Choice-Taq DNA polymerase (Denville) in the PTC-200 Peltier thermal cycler 
(MJ Research) under the following conditions: 95°C for 2 minutes, followed by thirty-
five cycles of 95°C for 15 seconds, 55°C for 30 seconds and 72°C for 60 seconds.  The 
final cycle was followed by a 5 minute extension step at 72°C.  Primer sequences used 
for both semi-quantitative and Real Time RT-PCR were as follows: GAPDH forward (5’-
ATC AAG AAG GTG GTG AAG CAG-3’, +946 to 966; NM_002046.4), GAPDH 
reverse (5’-TGT CGC TGT TGA AGT CAG AGG-3’, +1042 to 1022; NM_002046.4), 
MKP-1 forward (5’-GAA GTG GGC ACC CTG GAC GC-3’, +258 to 277; 
NM_004417.3), MKP-1 reverse (5’-TGG CCG GCG TTG AAA GCG AA-3’, +364 to 
345; NM_004417.3), MKP-2 forward (5’-GAG TCC GCG GTC CTC TCT CGT-3’, 
+494 to 515; NM_001394.6) and MKP-2 reverse (5’-CCT CGC GGT CAC ATA GCA 
GTC G-3’, +642 to 623; NM_001394.6).  Primers for MKP-1 and MKP-2 were 
generated using the Primer BLAST software from NCBI.  GAPDH primer sequences 
were used previously in the lab of Dr. Michael Tainsky.
73
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Real-Time PCR was carried out using the SYBR Green PCR core reagents kit 
(Applied Biosystems).  Each 20 µl reaction contained 2 mM MgCl2, 0.2 mM dNTPs, 0.1 
mM forward and reverse primer mixture, 2 µl cDNA, 2 µl 10X SYBR Green, 0.5 U 
AmpliTaq Gold Polymerase and sterile DNAse-RNAse free water (GIBCO).  Samples 
were run in 96 well plates using the Step One Plus Real-Time PCR System and Step One 
Plus Software version 2.1 (Applied Biosystems).  Thermal cycling was conducted 
according to the following protocol: 95°C for 10 minutes followed by forty cycles of 
95°C for 15 seconds and 60°C for 60 seconds.  Samples were then subjected to melt-
curve analysis to make sure the products were free of primer dimers.  Relative mRNA 
quantitation was calculated using the Ct method with GAPDH used as the internal 
control. 
shRNA 
CAOV3-pLKO.1 and CAOV3-shMKP-1 cells were generated in the Wu lab by 
Dr. Juan Wang.  Bacterial stocks of Mission shRNA (Sigma) directed against MKP-1 (5’-
CCGGCAAAGGAGGATACGAAGCGTTCTCGAGAACGCTTCGTATCCTCCTTTG
TTTTT-3’) were obtained and pLKO.1 vector DNA was stably transfected into CAOV3 
ovarian cancer cells using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol.  Positive clones were obtained after selection with puromycin. 
Four MKP-2 shRNAs subcloned into the pGIPZ vector (Open Biosystems) were 
tested.  The MKP-2 targeting sequences were as follows: shRNA 1(RHS4430-
101067857): CCCCAGTGGAAGATAACCACAA; shRNA 2 (RHS4430-101069298): 
ATTCGGTCAACGTGCGCTGTAA; shRNA 3 (RHS4430-101073316): 
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ACTGGTTCATGGAAGCCATAGA; shRNA 4 (RHS4430-98713911): 
AGCCTACCTGATGATGAAGAAA.  Constructs were transiently transfected into 
MCF7-MKP-2 cells using Lipofectamine 2000 according to the manufacturer’s protocol.  
Non-silencing shRNA was used as a negative control. 
Sequence Alignment 
Protein and DNA sequence alignments were performed with the ClustalW2 
software program from the European Bioinformatics Institute.  Default parameters were 
used.  Sequences were obtained from GenBank.  The following accession numbers were 
used:  MKP-1 mRNA (NM_004417.3), MKP-1 protein (NP_004408.1), MKP-2 mRNA 
(NM_001394.6) and MKP-2 protein (NP_001385.1). 
Generation of MKP-1 and MKP-2 Overexpressing Cell Lines 
Pooled populations of MCF7 cells overexpressing either MKP-1 [GenBank: 
BC022463] or MKP-2 [GenBank: BC002671.2] and subcloned into the pCDNA3.1 
expression vector were generated by stable transfection.  Cells were transfected using the 
Metafectine Easy transfection reagent (Biontex).  Briefly, 3 µl of metafectine was 
incubated in 100 µl phenol red free, serum free DMEM/F12 (1:1) medium for twenty 
minutes.  Five micrograms of the empty pCDNA3.1 vector, pCDNA3.1-MKP-1 construct 
or pCDNA3-MKP-2 construct DNA in 15 µl of DNAse-RNAse free water (GIBCO) 
were added to the metafectine and incubated at room temperature for twenty minutes to 
allow complexes to form.  The mixture was added drop-wise to the cells.  Stable clones 
expressing V5-His tagged MKP-1 or MKP-2 were selected with G418 antibiotic (500 
µg/mL) and pooled to minimize clonal bias.  Stable pools of MCF7 cells expressing 
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empty vector, MKP-1, or MKP-2 were maintained in DMEM/F12 (1:1) medium 
supplemented with 5% FBS, 10 µg/mL insulin, 0.5 nM 17-β-estradiol and 500 µg/mL 
G418. 
MTT Assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) assay 
was used to measure cell viability following drug treatment.  MCF7, MCF7-TAMR, 
MCF7-pCDNA3.1-Pool, MCF7-MKP-1-Pool or MCF7-MKP-2-Pool (1x10
3 
cells per 
well) were seeded in triplicate in 96 well plates (day 0) and treated with vehicle (EtOH, 
0.01% v/v), 10 nM E2, 100 nM TAM, 1000 nM TAM or a combination of 10 nM E2 and 
1-, 10- or 100-fold molar excess TAM (day 1).  Treatments were refreshed on day 4.    
Assays were  terminated on day 7 or when control wells reached 85% confluency, 
whichever was longer.  Cell viability was assessed by MTT assay (Sigma) and measured 
on a  Synergy 2 plate reader (BioTek) with Gen5 1.10 software. 
Results 
 Before beginning to study the relationship between MKP-1 and tamoxifen 
sensitivity, it was necessary to characterize its expression in breast cancer cell lines.  In 
order to select a cell line model to focus this study, a panel of breast cell lines was 
screened for MKP-1 protein expression.  This panel included the immortalized, non-
tumorigenic MCF10A cell line, the ER-negative MDA-MB-231 cells and ER-positive 
MCF7 cells.  MKP-1, a 39 kDa protein, was shown to be expressed in MDA-MB-231 
cells (Fig 6A, Lane 2). MKP-1 protein was not detected in MCF10A or MCF7 cells. A 43 
kDa band was shown to be highly expressed in MCF10A and MDA-MB-231 cells, but 
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was only weakly detected in MCF7 cells (Fig. 6A).  Similar results were seen in ER-
positive T47D cells (data not shown).  Real-time RT-PCR analysis showed that MCF10A 
and MDA-MB-231 cells express similar levels of both MKP-1 and MKP-2 mRNA, 
whereas MCF7 cells expressed low levels of both MKP-1 and MKP-2 mRNAs (Fig. 6B).  
The undetectable level of MKP-1 protein in MCF7 cells, as well as the low expression of 
the 43 kDa band, made it a good model to use for investigating the impact of MKP-1 
overexpression.   
Because the antibody used recognizes two bands, the ovarian cancer cell line 
CAOV3, which is known to highly express MKP-1, was used to confirm which band 
actually represents the protein.  Compared to cells transfected with a non-target shRNA 
(CAOV3-pLKO.1), cells transfected with MKP-1 shRNA (CAOV3-shMKP-1) showed a 
decrease in expression in the 39 kDa band, confirming that the 39 kDa band is MKP-1 
(Fig. 6C).  
The antibody being using for these studies is a polyclonal MKP-1 antibody from 
Santa Cruz.  The antibody epitope is located within the last 50 amino acids of the MKP-1 
C-terminus.  The C-terminal region of MKP-1 contains the catalytic site, which is highly 
conserved among MKP family members.
13
  MKP-2 is a 43 kDa protein and among the 
MKP family members it is most similar to MKP-1 in that it is also a nuclear phosphatase 
and is able to dephosphorylate all three MAPKs.
11
  To investigate whether the 43 kDa 
protein could be MKP-2, the amino acid sequences of both MKP-1 and MKP-2 were 
aligned using ClustalW2 software.  This analysis showed that 29 of the 50 amino acids in 
the MKP-1 antibody epitope are identical to those present in MKP-2 (Fig. 7).   To 
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confirm further that the 43 kDa band observed in the previous study is indeed MKP-2, 
four MKP-2 shRNA constructs from Open Biosystems were transiently transfected into 
MCF7 cells engineered to overexpress MKP-2 with a V5-His tag (MCF7-MKP-2 cells) 
and whole cell lysates prepared from these cells were analyzed by Western blot with 
MKP-1 antibody (Fig. 8).  It was found that shRNA constructs 3 and 4 greatly reduced 
expression of both the 43 kDa band and the V5-His tagged band compared to the non-
target control.  From this analysis it can be concluded that the 43 kDa band is MKP-2 and 
that the MKP-1 antibody recognizes both MKP-1 and MKP-2 proteins. 
Previous work in the field has demonstrated that MKP-1 expression can be altered 
following drug treatment.
58,60,61
  After determining that MCF7 is an appropriate cell line 
model, cells that were engineered to overexpress MKP-1 (MCF7-MKP-1 cells) were used 
to investigate whether MKP-1 protein expression is altered following treatment with E2, 
E2 plus 100-fold molar excess TAM or TAM alone (Fig. 9).  Both the MCF7-MKP-1 and 
MCF7-MKP-2 cells were derived from single clonal populations following positive 
selection with G418 antibiotic.  Cells were plated in phenol red free media and treated 
with 1 or 10 nM E2, 100 nM or 1 µM TAM or the combination of E2 and TAM for 24 hr.  
In both the vector control cells and MCF7-MKP-1 cells, no obvious change in MKP-1 
protein expression was observed. 
Interestingly, a small but noticeable increase in the expression of MKP-2 was 
observed in both the vector control and MCF7-MKP-1 cell lines following tamoxifen 
treatment when compared with the vehicle control (Fig. 9, Vector Control Lanes 5-7, 
MCF7-MKP-1 Lanes 7-9).  Since endogenous MKP-2 is increased by tamoxifen  
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Figure 6.  MKP-1 and MKP-2 protein and mRNA expression in breast cell lines.  A. 
Western blot showing the protein expression levels of MKP-1 (39 kDa) and MKP-2 (43 
kDa) in a panel of breast cell lines.  Whole cell lysates were probed with anti-MKP-1 
antibody. Actin was used as a loading control.  B. Real-Time RT-PCR analysis was used 
to measure mRNA expression levels of MKP-1 and MKP-2 in the same panel of breast 
cell lines.  Relative mRNA levels were determined using the ΔΔCt method.  GAPDH was 
used as the internal control.  Results are representative of at least three independent 
experiments with each sample in triplicate.  Error bars represent the standard error of the 
mean.  C.  CAOV3 ovarian cancer cells were stably transfected with either a non-target 
shRNA or shRNA toward MKP-1.  Whole cell lysates were probed with anti-MKP-1 
antibody.  Actin was used as a loading control. 
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Figure 7.  MKP-1 and MKP-2 Amino Acid Sequence Alignment.  The amino acid 
sequences of MKP-1 and MKP-2 were aligned using the ClustalW2 software in order to 
determine if the epitope of the MKP-1 antibody used in these studies could also recognize 
MKP-2.  Boxed area indicates the sequence containing the epitope of the MKP-1 
antibody.  Identical residues are shown in white. 
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Figure 8.  The 43 kDa protein recognized by the MKP-1 antibody is MKP-2.  MCF7 
cells engineered to overexpress MKP-2 with a V5-His tag were transiently transfected 
with either a non-target control shRNA or one of four shRNA constructs targeting MKP-
2.  Constructs 3 and 4 showed the ability to decrease MKP-2 and MKP-2-V5-His protein 
expression.  Whole cell lysates were probed with anti-MKP-1 antibody.  Actin was used 
as a loading control. 
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Figure 9.  MKP-1 protein expression is unchanged, but MKP-2 protein expression 
increases following tamoxifen treatment.  A.  MCF7 vector control cells were treated 
for 24 hrs. with either vehicle, 1 nM E2, 10 nM E2, 1 nM E2 and 100 nM TAM, 10 nM E2 
and 1000 nM TAM, 100 nM TAM or 1000 nM TAM.  Whole cell lysates were analyzed 
by Western blot and membrane was probed with anti-MKP-1 antibody.  Actin was used 
as a loading control.  B.  MCF7-MKP-1 cells were treated as described in panel A.  
Whole cell lysates were analyzed by Western blot and membrane was probed with anti-
MKP-1 antibody.  Actin was used as a loading control. VC = MCF7 vector control cells. 
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treatment, it suggests that MKP-2 expression may be regulated in an ER-mediated 
manner.  This possibility will be investigated in greater depth in subsequent chapters. 
Next, it was necessary to investigate whether MKP-1 overexpression contributes 
to changes in tamoxifen sensitivity.  MTT assays were used to assess the effects of MKP-
1 overexpression on tamoxifen sensitivity.  The assay was first conducted with parental 
MCF7 cells, which are tamoxifen sensitive.  These cells were plated in phenol red free 
medium supplemented with charcoal stripped serum to minimize any baseline estrogenic 
effects 
74
.  On the following day, cells were treated with vehicle (EtOH, 0.01% v/v), 10 
nM E2, 1000 nM TAM or a combination of 10 nM E2 and 100 or 1000 nM TAM.  
Treatments were refreshed on Day 4 and the assay was allowed to continue for seven 
days.  Treatment with E2 showed approximately a 2.5 fold increase in cell proliferation 
(p<0.01) and this increase was blocked by the addition of tamoxifen (Fig. 10A).  These 
results demonstrate that the MCF7 cells used in this study are indeed E2 responsive and 
tamoxifen sensitive.   
Before looking at the effect of MKP overexpression on TAM sensitivity, pooled 
populations of MCF7 cells engineered to stably overexpress either MKP-1 or MKP-2 
were generated to better reflect the heterogeneity known to be present in human tumors.  
These cell lines express MKP-1 or MKP-2 with a V5-His tag.  Western blot analysis was 
conducted to confirm the presence of the V5 tag, which was expressed at the expected 
size of MKP-1 at 43 kDa and MKP-2 at 48 kDa.  The results of this analysis showed that 
the V5 tag is present in the MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells, but not in 
MCF7-pCDNA3.1-Pool cells (Fig. 10B). MCF7-pCDNA3.1-Pool cells and MCF7-MKP-
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1-Pool cells were then subjected to MTT analysis (Fig. 10C).  This assay was carried out 
in regular medium because the cells were very sensitive to E2 withdrawal and showed 
poor viability in phenol red-free medium.  Treatment with E2 doubled proliferation 
(p<0.01) of MCF7-pCDNA3.1-Pool cells compared to vehicle control.  Treatment with 
TAM in the presence of E2 blocked this increase and cell proliferation was further 
decreased with TAM alone.  In the MCF7-MKP-1-Pool cells, overexpression of MKP-1 
almost completely eliminated the E2-induced increase in cell proliferation.  Treatment 
with E2 plus TAM or TAM alone reduced cell proliferation by similar amounts compared 
to vehicle control. The results of this assay suggest that overexpression of MKP-1 does 
not increase the sensitivity of MCF7 cells to tamoxifen, but that it does decrease cell 
proliferation in the presence of estrogen.   
The decrease in cell proliferation in the presence of estrogen following MKP-1 
overexpression suggests that the activity of MKP-1 is directed toward the MAPK that 
drives the proliferation of these cells.  To further investigate this, activation of two 
MAPKs closely associated with cell growth, ERK1/2 and JNK1/2, was examined in 
MCF7-pCDNA3.1-Pool and MCF7-MKP-1-Pool cells.  Preliminary experiments failed to 
detect p38 protein expression (data not shown), so it was not included in any further 
experiments.  MCF7-pCDNA3.1-Pool and MCF7-MKP-1 Pool cells were plated in 
phenol red-free medium and treated with either vehicle (EtOH, 0.01% v/v), E2, the 
combination of E2 plus TAM, TAM alone, the combination of E2 and ICI 182,170 (ICI) 
or ICI alone for four hours.  This time point was chosen based on previous time course 
experiments (data not shown).  MCF7 cells that were serum-starved overnight and then 
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treated with serum for 10 minutes were used as the positive control for ERK1/2 
phosphorylation.  Basal levels of phospho-ERK1/2 were observed in vector controls that 
were not affected by treatment.  This activity was completely eliminated following MKP-
1 overexpression (Fig. 11A).  MCF7 cells treated with 10 ng/mL anisomycin for 30 
minutes served as the positive control for JNK1/2 phosphorylation.  JNK1/2 activation 
was not detected in either cell line (Fig. 11B), suggesting that ERK1/2 signaling is a 
major driver of MCF7 cell proliferation. 
Conclusion 
 The MAP Kinase phosphatase MKP-1 has been linked to chemotherapy resistance 
and is known to exhibit altered expression in many different cancer types, including 
breast.  This previous work led to the formulation of the hypothesis that an increase in 
MKP-1 expression is associated with changes in breast cancer tamoxifen sensitivity.  In 
order to study this association, breast cell lines were screened for MKP expression.  The 
low expression of MKP-1 and MKP-2 in MCF7 cells made this cell line an ideal 
candidate to study the effects of the overexpression of MKP-1 in breast cancer.  The first 
step was to examine the effect of E2 and TAM treatment on MKP-1 protein expression.  
Treatment with E2, TAM or their combination revealed no obvious change in MKP-1 
protein expression.  E2 is known to increase cell proliferation by upregulating growth 
factor pathways.
22,35
  TAM treatment blocks this activation.  MKP-1 overexpression 
failed to change tamoxifen sensitivity, exhibiting a similar cell viability profile to 
tamoxifen-sensitive MCF7 vector control cells.  MKP-1 overexpression did decrease cell 
proliferation in the presence of E2 and examination of ERK1/2 and JNK1/2 activation in 
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those cells showed that, compared to vector control cells, ERK1/2 phosphorylation was 
completely eliminated and that JNK1/2 activation was not present in either cell line.  
These data indicate that, contrary to the study hypothesis, MKP-1 does not play a role in 
contributing to changes in breast cancer tamoxifen sensitivity.  However, MKP-2 protein 
expression was increased following tamoxifen treatment.  This result suggests that MKP-
2 expression might be regulated via an ER mediated mechanism and that changes in 
MKP-2 expression could play a role in contributing to changes in tamoxifen sensitivity. 
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Figure 10.  MKP-1 Overexpression Does Not Alter Tamoxifen Sensitivity.  A. MCF7 
cells were treated with Vehicle, E2, E2+TAM or TAM alone and subjected to MTT 
analysis.  Cells were treated on days 1 and 4.  Absorbance was read on day 7.  Results are 
representative of at least three independent experiments with samples plated in triplicate.  
Error bars represent the standard error of the mean.  Statistical analysis was done using 
Student’s t-test.  ** = p<0.01  B.  Western blot depicting the expression of the V5 tag in 
MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells.  Population was selected with G418 
antibiotic for one month and whole cell lysates were probed with V5 antibody.  GAPDH 
was used as a loading control.  C.  MCF7-pCDNA3.1-Pool and MCF7-MKP-1-Pool cells 
were treated with Vehicle, E2, E2+TAM or TAM alone and subjected to MTT analysis.  
Cells were treated on days 1 and 4.  Absorbance was read on day 7.  Results are 
representative of at least three independent experiments with samples plated in triplicate.  
Error bars represent the standard error of the mean.  Statistical analysis was done using 
Student’s t-test.  ** = p <0.01 
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Figure 11.  MKP-1 Overexpression Eliminates ERK1/2 activation.  A.  MCF7-
pCDNA3.1-Pool cells and MCF7-MKP-1-Pool cells were treated with vehicle, E2, the 
combination of E2+TAM, TAM alone, the combination of E2+ICI or ICI alone for four 
hours.  Serum-starved MCF7 cells were treated for 10 min. with serum and used as a 
positive control for ERK1/2 phosphorylation.  Whole cell lysates were analyzed by 
western blot and membranes were probed with either phospho-ERK1/2 (P-ERK1/2) or 
Total ERK1/2 antibody.  GAPDH was used as a loading control.  B.  MCF7-pCDNA3.1-
Pool and MCF7-MKP-1-Pool cells were treated as described in panel A.  MCF7 cells 
treated with 10 ng/mL anisomycin for 30 minutes were used as a positive control for 
JNK1/2 phosphorylation.  Whole cell lysates were analyzed by western blot.  Membranes 
were probed with either phospho-JNK1/2 (P-JNK1/2) or Total JNK1/2 antibody.  
GAPDH was used as a loading control.  
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CHAPTER 3 
CHARACTERIZATION OF MKP-2 IN BREAST CANCER TAMOXIFEN 
SENSITIVITY 
Introduction 
 The data presented thus far show that MKP-1 overexpression does not change 
tamoxifen sensitivity of MCF7 cells, that MKP-1 protein expression is not obviously 
altered after treatment with estrogen, tamoxifen or their combination and that MKP-2 
protein expression increases under these conditions.  These data suggest MKP-2, rather 
than MKP-1, might be a player in tamoxifen sensitivity of MCF7 cells.     
 Next to MKP-1, MKP-2 is the best characterized MKP, although considerably 
less is known about its role in cancer and chemotherapy resistance.  MKP-2 was first 
identified by Misra-Press et al in 1994.
54
  The authors of this study demonstrated that 
MKP-2 is expressed in a wide variety of rat tissues in a profile that is overlapping yet 
distinct from MKP-1.  They also suggested that this differential expression combined 
with the unique N-terminal sequences of the two phosphatases indicate distinct functional 
roles for each protein.
54
 
 Subsequent work by this group investigated the ability of MKP-1 and MKP-2 to 
dephosphorylate the stress-activated MAPK, JNK.
75
  Their analysis revealed that MKP-1 
was better able to dephosphorylate JNK-1 than MKP-2 and that both phosphatases 
showed similar abilities to dephosphorylate JNK-2.
75
  Further analysis of MKP-2 
substrate specificity showed that it is also able to dephosphorylate ERK1/2, but had little 
effect on p38.
11
 These analyses of substrate specificity were conducted using 
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exogenously expressed proteins.  Additionally, MKP-2 substrate specificity has not been 
examined in the context of tamoxifen sensitivity.  Recently, MKP-2 knockout mice were 
created to study MKP-2 physiological function.  This study showed that deletion of 
MKP-2 decreased cell proliferation and cell cycle analysis showed that MKP-2
-/-
 MEFS 
accumulated in the G2/M phase, suggesting that MKP-2 might play a role in cell cycle 
progression.
76
 
Studying the transcriptional regulation of MKP-2 has provided insight into its 
possible mechanistic role in cancer.  Evidence has been put forth that MKP-2 is a 
transcriptional target of p53 in response to oxidative stress.  This would seem to be 
consistent with the idea that MKP-2 might play a role in cell cycle regulation.
77
  The 
authors of this study suggested that MKP-2 might contribute to tumor suppression
77
, 
which is certainly contrary to the notion that it would play a role in cell cycle 
progression.  MKP-2 has also been identified as a transcriptional target of E2F-1. E2F-1
-/-
 
MEFs showed decreased levels of H2O2-induced MKP-2 protein compared to E2F-1
+/+ 
MEFs and also displayed resistance to oxidative stress induced cell death
78
.  When MKP-
2 was overexpressed in MCF7 cells, these cells were more sensitive to H2O2 treatment 
than vector control cells.  MCF7 cells overexpressing MKP-2 also showed decreased 
colony formation in soft agar compared to vector control.
78
  When injected into female 
athymic nude mice, MCF7-MKP-2 cells formed tumors in 2 of 12 mice, whereas all mice 
injected with vector control cells formed tumors.
78
 
The exploration of the expression of MKP-2 in cancer has been limited thus far.  
As discussed in Chapter 1, its expression levels have been examined in pancreatic
44
, 
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liver
43
, ovarian
9
 and breast cancers
24
, as well as in glioblastomas
45
.  MKP-2 expression 
has been shown to be upregulated in all of these cancer types, with the exception of 
ovarian cancer and glioblastoma.  In primary tumors as well as in glioblastoma cell lines, 
methylation of a CpG island in the MKP-2 promoter was detected.
45
  MKP-2 promoter 
methylation was found to occur more frequently in tumors with p53 mutation, but in 
tumors with amplified EGFR it was virtually absent.  Additionally, the overexpression of 
MKP-2 in glioma cell lines showed a decrease in cell proliferation, furthering the idea 
that MKP-2 plays a role in growth suppression.
45
  Another study that supports this idea 
showed that the MKP-2 promoter was more highly methylated in basal-like breast tumors 
resected following neo-adjuvant chemotherapy compared to other breast cancer subtypes 
and overexpression of MKP-2 in these tumors increased chemotherapy-induced 
apoptosis.
79
  These results suggest that loss of MKP-2 expression may contribute to 
chemotherapy resistance. 
 Prior to the work presented in this chapter, no connections had been made 
between MKP-2 expression and the role it plays in regard to tamoxifen sensitivity.  To 
investigate this, MKP-2 gene and protein expression were characterized in tamoxifen 
sensitive and tamoxifen resistant cells, along with the effect of MKP-2 overexpression on 
cell proliferation following tamoxifen treatment.  The putative promoter of MKP-2 has 
also been identified in order to study the regulation of MKP-2 gene expression in 
response to estrogen and tamoxifen treatments.  The studies presented here collectively 
show that MKP-2 is expressed in tamoxifen resistant cells, that  overexpression of MKP-
2 decreases cell proliferation in response to estrogen yet maintains tamoxifen sensitivity, 
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and that MKP-2 promoter activity is not changed following E2 or TAM treatment.  These 
data suggest that in the context of tamoxifen resistance, MKP-2 may be upregulated to 
return the cell to a tamoxifen sensitive phenotype. 
Materials and Methods 
 Cell culture, generation of whole cell lysates, Western blot analyses, MTT assays, 
RNA isolation and real-time RT-PCR were conducted as described in the Materials and 
Methods section of Chapter 2. 
Identification of the Putative MKP-2 Promoter 
 The putative promoter of MKP-2 was identified using the Genomatix software 
suite by entering DUSP4 in the Gene2Promoter database and aligning the resulting 
sequences with the gene sequence of MKP-2 (gene id 1846).  The promoter sequence that 
was determined to be the best match was GXP_35747, a 1207 bp sequence on the 
negative strand of chromosome 8 from bp 29,208,769 to 29,207,563.  Transcription 
factor binding sites were identified using the MatInspector program. 
Amplification of the MKP-2 Promoter  
 The promoter of MKP-2 was amplified from human placental genomic DNA 
using primers containing XhoI (forward primer) and HindIII (reverse primer) restriction 
sites to facilitate the cloning of the promoter into the appropriate vectors.  The primer 
sequences were as follows: MKP-2-pro-XhoI (5’-CCG CTC GAG GGC TGT CAC GCG 
GGG AAG CG-3’; +1 to 20; Genomatix accession id: GXP_35747) and MKP-2-pro-
HindIII (5’-CCC AAG CTT TTA GCC CGC CGC CGC ACG AT-3’; +1207 to 1188; 
Genomatix accession id: GXP_35747).  The MKP-2 promoter was amplified using 
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Choice Taq DNA polymerase (Denville) in a PTC-200 Peltier thermal cycler under the 
following conditions: 95°C for 5 min, followed by 35 cycles of a 1 min, 95°C denaturing 
step, 2 min, 55°C annealing step and 3 min, 72°C extension step.  Upon the completion 
of 35 cycles, a 10 minute final extension step was performed at 72°C.  
Cloning of the MKP-2 Promoter 
 The putative MKP-2 promoter was cloned into the pCR-TOPO4 TA cloning 
vector (Invitrogen).  The fragment containing the putative MKP-2 promoter was released 
from the TA cloning vector using the EcoRI (Invitrogen) restriction sites according to the 
manufacturer’s protocol.  The promoter fragment was subsequently digested with XhoI 
and HindIII and subcloned into the pGL3-Basic Luciferase Reporter vector (Promega) 
using the XhoI and HindIII (New England Biolabs) restriction sites according to the 
manufacturer’s protocol.  
Sequencing  
 Sequencing of the pCR4-MKP-2 promoter construct was carried out by Genewiz 
using the M13 forward (5’-ACT GGC CGT CGT TTT AC-3’) and reverse (5’-ACA 
GGA AAC AGC TAT GA-3’) priming sites found on the pCR4-TOPO vector.  After 
subcloning the MKP-2 promoter into the pGL3-Basic vector, the construct was 
sequenced by Genewiz using the MKP-2-pro-XhoI (forward) and MKP-2-pro-HindIII 
(reverse) primers (see Cloning section above for sequences) as well as the GLprimer2 
primer (5’-TGG AAG ACG CCA AAA ACA TAA AG-3’), which recognizes the 
luciferase transcription start site present in the pGL3-Basic vector. 
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Transfection and Luciferase Reporter Assay 
Transfection of the empty pGL3 and pGL3-MKP-2-pro constructs into MCF7, 
MCF7-TAMR and MDA-MB-231 cells (2.5 x 10
5
 cells per well in 6 well plates) was 
carried out using the Metafectine Easy transfection reagent (Biontex).  Briefly, 5 µl of 
metafectine was incubated in 100 µl phenol red free, serum free DMEM/F12 (1:1) 
medium for twenty minutes.  Five micrograms of either empty pGL3 or pGL3-MKP-2-
pro DNA and 0.5 ng of pRLTK (expressing Renilla luciferase and serving as an internal 
control) in 15 µl of DNAse-RNAse free water (GIBCO) was added to the metafectine 
and incubated at room temperature for twenty minutes to allow complexes to form.  The 
mixture was added drop-wise to the cells.   Vehicle, E2, TAM or ICI treatments were 
added 24 hrs post-transfection.  Luciferase reporter activity was measured 48 hrs post-
transfection using the Dual Luciferase Reporter Assay System (Promega) according to 
the manufacturer’s protocol.  The TD-20/20 luminometer (Turner Designs) was used to 
read the luciferase activity of each sample. 
Results 
The data presented thus far show that overexpression of MKP-1 does not change 
tamoxifen sensitivity in MCF7 cells and that MKP-2 protein was increased with 
tamoxifen treatment.  It was important to verify a potential role for MKP-2 in tamoxifen 
sensitivity under physiological conditions.  This was done with an isogenic model of 
acquired tamoxifen resistance (MCF7 and MCF7-TAMR cells).  MCF7 cells that had 
been selected with increasing amounts of tamoxifen for over six months (MCF7-TAMR 
cells) were obtained from the lab of Dr. Malathy Shekhar.  MKP protein expression in 
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these cells was determined by western blot analysis and it was shown that as compared to 
parental MCF7 cells, MKP-2 protein expression was 3.5–fold higher and that MKP-1 
protein expression was not detectable (Fig. 12A).  This was supported by real-time PCR 
analysis, which showed that MKP-2 mRNA was increased 12-fold in tamoxifen resistant 
cells when compared to parental MCF7 cells and that MKP-1 mRNA expression was 
negligible (Figure 12B).  
To further characterize the MCF7-TAMR cells, MTT analysis was carried out in 
phenol red free medium as described previously.  It was found that these cells showed a 
modest increase in proliferation when treated with 10 nM E2 and that tamoxifen treatment 
did not block this increase, but in fact further stimulated cell proliferation.  This indicates 
that these cells are not sensitive to estrogen and are indeed tamoxifen resistant (Fig 12C).  
Since it has been shown that phosphorylation of Ser118 in the estrogen receptor leads to 
its ligand-independent activation and it has been suggested that this site is associated with 
tamoxifen resistance, phosphorylation of this site in MCF7 and MCF7-TAMR cells was 
examined (Fig. 13).  Cells were plated in phenol red-free medium and treated with 
vehicle (EtOH, 0.01% v/v), 10 nM E2, 1 µM tamoxifen, the combination of E2 and 100-
fold molar excess tamoxifen, the combination of 10 nM E2 and 100-fold molar excess ICI 
or 1 µM ICI for 4 hours.  In both cell lines, estrogen treatment increased Ser118 
phosphorylation.  This increase was reduced by treatment with anti-estrogens. 
Additionally, MKP-2 protein expression in MCF7 (Fig. 13A) and MCF7-TAMR (Fig. 
13B) cells under these conditions was examined. In MCF7 cells, MKP-2 levels were  
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Figure 12.  Characterization of MCF7-TAMR Cells. A. MKP-2 protein expression is 
increased in MCF7-TAMR cells compared to MCF7 parental cells.  Whole cell lysates 
were analyzed by western blot and probed with anti-MKP-1 antibody.  MCF7-MKP-1 
cells were included as a positive control for MKP-1 expression. B. MKP-2 mRNA 
expression is increased in MCF7-TAMR cells compared to MCF7 parental cells.  Gene 
expression was detected by qRT-PCR.  GAPDH was used as an internal control.  Results 
are representative of two independent experiments.  Samples were plated in triplicate.  
Error bars represent the standard error of the mean.  C. MCF7 and MCF7-TAMR cells 
were treated with vehicle, E2, E2+TAM or TAM alone and subjected to MTT analysis.  
Cells were treated on days 1 and 4.  Absorbance was read on day 7.  Results are 
representative of at least three independent experiments with samples plated in triplicate.  
Statistical analysis was done with Student’s t-test.  ** = p<0.01 
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Figure 13.  MKP-2 protein expression is increased following anti-estrogen treatment 
in MCF7 cells and constitutively expressed in MCF7-TAMR cells. A. MCF7 cells 
were treated with vehicle, E2, E2+TAM, TAM alone, E2+ICI or ICI alone for 4 hours in 
phenol red free medium.  Whole cell lysates were subjected to western blot analysis and 
probed with antibody toward P-S118, total ERα, or MKP-2.  Actin was used as a loading 
control. B. MCF7-TAMR cells were treated with vehicle, E2, E2+TAM, TAM alone, 
E2+ICI or ICI alone for 4 hrs in phenol red free medium.  Whole cell lysates were 
subjected to western blot analysis and probed with antibody toward P-S118, total ERα or 
MKP-2.  Actin was used as a loading control. 
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slightly increased with anti-estrogen treatment, which is similar to what was observed in 
vector control and MKP-1 overexpression cells previously (Fig. 9).  In MCF7-TAMR 
cells, however, MKP-2 was shown to be constitutively expressed, regardless of treatment 
condition.  MKP-1 expression was not detected in either cell line. 
To study MAP Kinase activation in these cells, levels of phosphorylated ERK1/2 
in both MCF7 and MCF7-TAMR cells following 4 hour treatment with 10 nM E2, 1 µM 
tamoxifen, 1 µM ICI or the combination of estrogen and tamoxifen or estrogen and ICI 
were examined (Fig. 14).  MCF7 cells that were serum-starved overnight and 
subsequently treated with serum for 10 minutes served as a positive control for ERK1/2 
phosphorylation.  Following treatment with E2, basal ERK1/2 phosphorylation in MCF7 
cells was observed at a similar level as vehicle control and this phosphorylation was 
decreased following treatment with E2 plus TAM, TAM alone, E2 plus ICI and ICI alone, 
suggesting that levels of phosphorylated ERK1/2 in MCF7 cells are responsive to anti-
estrogen treatment (Fig. 14A).  Previous work in the field has shown that treatment of 
MCF7 cells with E2 induces ERK1/2 phosphorylation to a much greater extent than 
shown here.
80
  This is possibly due to the absence of phosphatase inhibitors in the lysis 
buffer used to generate whole cell lysates.  In MCF7-TAMR cells, ERK1/2 activation 
was present regardless of treatment condition (Fig. 14B).  JNK1/2 activation was also 
examined in both cell lines, with MCF7 cells treated with anisomycin for 30 minutes 
serving as a positive control.  JNK1/2 phosphorylation could not be detected in either 
MCF7 (Fig. 14A) or MCF7-TAMR cells (Fig. 14B). 
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As mentioned in Chapter 2, in order to study the role of MKP-2 in tamoxifen 
sensitivity, a pooled population of MCF7 cells engineered to overexpress MKP-2 was 
generated.  MKP-2 protein expression was measured in the MCF7-pCDNA3.1-Pool cells 
and the MCF7-MKP-2-Pool cells (Fig. 15A).  MKP-2 expression was low in MCF7-
pCDNA3.1-Pool cells.  In the MCF7-MKP-2-Pool cells, endogenous MKP-2 expression 
was present at low levels, while exogenous MKP-2 expression was present at higher 
levels.  These cells were then used to perform an MTT assay under the same treatment 
conditions described previously (Fig. 15B).  The vector control cells used in this 
experiment were the same as those used in Fig. 10.  MCF7-MKP-2-Pool cells showed a 
decreased response to estrogen, but maintained tamoxifen sensitivity.  These data suggest 
that MKP-2 overexpression inhibits cell proliferation in response to estrogen, but retains 
sensitivity to tamoxifen. 
As noted earlier, in MCF7-TAMR cells, MKP-2 protein expression is increased 
compared to MCF7 cells and is constitutively expressed regardless of treatment 
condition.  To further assess the role of MKP-2 activity in the context of tamoxifen 
response, MCF7-pCDNA3.1-Pool, MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cells 
were treated with vehicle, E2 or the combination of E2 and one of three increasing 
concentrations of TAM and cell proliferation was analyzed using an MTT assay (Fig. 
15C).  Compared to the vector control cells, overexpression of MKP-2 caused a 
significant (p<0.05) decrease in cell proliferation following E2 treatment.  Treatment with 
a combination of E2 with 1, 10 or 100-fold molar excess TAM resulted in dose-dependent 
inhibition of MCF7-MKP-1-Pool and MCF7-MKP-2-Pool cell proliferation. 
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Figure 14.  Phosphorylation of ERK1/2 in MCF7 cells is responsive to anti-hormone 
treatment.  A.  MCF7 cells were treated with vehicle, E2, E2+TAM, TAM alone, E2+ICI 
or ICI alone for 4 hours in phenol red free medium.  Serum starved MCF7 cells were 
treated with serum for 10 minutes and were included as a positive control for ERK1/2 
phosphorylation.  MCF7 cells treated with 10 ng/mL anisomycin for 30 minutes were 
included as a positive control for JNK1/2 phosphorylation.  Whole cell lysates were 
subjected to western blot analysis and probed with antibody toward P-ERK1/2, total 
ERK1/2, P-JNK1/2 or total JNK1/2.  GAPDH was used as a loading control.  B.  MCF7-
TAMR cells were treated as described in Panel A. 
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Figure 15.  Overexpression of MKP-2 affects cell proliferation in response to E2, and 
increases TAM sensitivity compared to vector control and MKP-1 overexpressing 
cells. A. Whole cell lysates of MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool were 
treated with vehicle, E2, E2+TAM, TAM, E2+ICI or ICI for 4 hours, then subjected to 
western blot analysis and probed with antibody toward MKP-1.  GAPDH was used as a 
loading control.  B. MCF7-pCDNA3.1-Pool cells and MCF7-MKP-2-Pool cells were 
treated with vehicle, 10 nM E2, E2+TAM, 100 nM TAM or 1000 nM TAM and MTT 
analysis was performed.  Cells were treated on days 1 and 4.  Absorbance was read on 
day 7.  Results are representative of at least three independent experiments with samples 
plated in triplicate.  Statistical analysis was done using Student’s t-test.  ** = p<0.01 C.  
MCF7-pCDNA3.1-Pool cells, MCF7-MKP-1-Pool cells and MCF7-MKP-2-Pool cells 
were treated with vehicle, E2 or E2 plus one of three increasing concentrations of TAM 
and and MTT assay was performed.  Cells were treated on days 1 and 4 and absorbance 
was read on day 7.  Results are representative of two independent experiments with 
samples plated in triplicate.  Statistical analysis was done using Student’s t-test.  * = 
p<0.05, ** = p <0.01, *** = p<0.001 
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Compared to vector control or MKP-1 overexpressing cells, MKP-2 overexpressing cells 
were associated with greater tamoxifen sensitivity as significant (p<0.01) decreases were 
observed at all three doses of tamoxifen. 
 To identify the MAPK that MKP-2 was inactivating, ERK1/2 and JNK1/2 
phosphorylation were measured by western blot (Fig. 16).  The vector control cells 
shown here are the same as those in Fig. 11.  As discussed before, basal ERK1/2 
activation was observed and JNK1/2 activation was not present in these cells (Fig. 16A).  
MKP-2 overexpression completely abolished ERK1/2 activity.  As expected, no JNK1/2 
phosphorylation was detected (Fig. 16B), suggesting that ERK1/2 is a major driver of 
proliferation in these cells. 
The increase in MKP-2 protein expression following treatment with tamoxifen 
suggested that the MKP-2 promoter might be regulated via an ER-mediated mechanism.  
In order to investigate this, the Genomatix software suite was used to identify the putative 
promoter for MKP-2, and MatInspector was used to locate putative transcription factor 
binding sites.  This analysis revealed that there are three estrogen response element 
(ERE) half sites within the putative promoter sequence, two on the negative strand, which 
is the DNA strand containing the MKP-2 gene, and one on the positive strand.  Fig. 17 
shows the MKP-2 gene with the promoter region, and the putative ERE half sites.  
Although these are not canonical EREs in the sense that a full response element is not 
present, the presence of a single ERE half site has been shown to be sufficient to  
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Figure 16.  Overexpression of MKP-2 eliminates ERK1/2 phosphorylation.  A.  
MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool cells were plated in phenol red-free 
medium and treated with vehicle, E2, E2+TAM, TAM, E2+ICI or ICI for 4 hours.  Whole 
cell lysates were analyzed by western blot and probed with either P-ERK1/2 or total 
ERK1/2 antibody.  Serum starved MCF7 cells treated with serum for 10 minutes were 
used as positive control for ERK1/2 phosphorylation.  GAPDH was used as a loading 
control.  B.  MCF7-pCDNA3.1-Pool and MCF7-MKP-2-Pool cells were treated as 
described in Panel A.  Whole cell lysates were analyzed by western blot and probed with 
either P-JNK1/2 or total JNK1/2 antibody.  MCF7 cells treated with 10 ng/mL 
anisomycin for 30 minutes were included as a positive control for JNK1/2 
phosphorylation.  GAPDH was used as a loading control. 
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produce a response to estrogen if stabilized through interactions with another 
transcription factor.
30  Interestingly, these ERE half sites in the putative MKP-2 promoter 
are located in very close proximity to canonical AP-2 response elements.  
To study MKP-2 promoter regulation, the MKP-2 promoter was amplified from 
human placental genomic DNA.  The promoter fragment was subcloned into the pCR4-
TOPO TA cloning vector.  After obtaining a clone positive for the MKP-2 promoter, it 
was verified by sequencing using M13 primers that recognize the pCR4 vector sequence.  
Sequence analysis confirmed that the insert was the MKP-2 promoter and that no 
mutations had been introduced during the amplification and cloning process.  The next 
step was to subclone the promoter into the pGL3-Basic vector.  This was done using the 
XhoI and HindIII restriction sites.  Restriction digest analysis was performed with the 
XhoI and HindIII enzymes and showed that the insert was the same size obtained from 
the TA cloning vector (Fig. 18).  The presence of the MKP-2 promoter was verified by 
sequencing with the primers initially used to isolate it, as well as a primer that recognized 
the transcription start site of the luciferase reporter gene present in the pGL3-Basic 
vector.  The results of both of these sequencing reactions confirmed the presence of the 
MKP-2 promoter and that no mutations were introduced during cloning.   
Once the MKP-2 promoter-driven luciferase reporter construct was created, its 
activity was tested in MDA-MB-231 cells, as MDA-MB-231 cells express high levels of 
MKP-2 mRNA (Fig. 6), indicative of elevated MKP-2 promoter activity.  The cells were 
transfected with either the empty pGL3, or 2, 3, 5 or 10 µg of the pGL3-MKP-2-pro  
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 Figure 17.  The putative MKP-2 promoter contains ERE half sites.  Schematic 
depicting the sequence features of the MKP-2 promoter, including estrogen response 
element half sites and AP-2 transcription factor binding sites.   
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Figure 18.  The putative MKP-2 promoter is subcloned into the pGL3-Basic 
Luciferase Reporter vector.  Following TA cloning and subcloning into pGL3-Basic 
vector, constructs underwent restriction digest analysis with XhoI and HindIII to confirm 
presence of MKP-2 promoter insert. Products were run on a 1% agarose gel.  
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construct with Renilla luciferase used as an internal control.  MKP-2 promoter-driven 
luciferase was expressed robustly in MDA-MB-231 cells and increased with increasing 
amounts of MKP-2 promoter DNA transfection (Fig. 19A).  These data suggest that the 
putative MKP-2 promoter sequence possesses promoter activity.  Next, the pGL3-MKP-
2-pro construct was transfected into MCF7 and MCF7-TAMR cells.  Cells were plated in 
phenol red free medium and transfected with 5 µg of either the pGL3-Basic vector or the 
pGL3-MKP-2-pro construct along with pRLTK.  On the day following transfection, cells 
were treated with vehicle (EtOH, 0.01% v/v), 10 nM E2, 1 µM TAM, 1 µM ICI or the 
combination of E2 plus TAM or E2 plus ICI.  Levels of basal reporter gene activation in 
MCF7 and MCF7-TAMR cells were substantially lower than in the ER-negative MDA-
MB-231 cells, and treatment with E2, TAM or ICI did not alter the basal activity in MCF-
7 and MCF-7-TAMR cells.   Since promoter activity was seen in MDA-MB-231 cells, 
this suggests the presence of functional transcription regulatory elements in the 1207 bp 
fragment used for MKP-2 promoter analysis.  The weak activity exhibited in MCF7 and 
MCF7-TAMR cells may be due to low transfection efficiency, as Renilla luciferase levels 
were much lower in MCF7 and MCF7-TAMR cells as compared to MDA-MB-231 cells.  
Since the basal activities of the promoter construct were unaffected by hormones, it is 
possible that  the hormonal response elements capable of regulating MKP-2 promoter 
activity reside outside the selected DNA fragment, or that MKP-2 gene expression is not 
controlled by classical ER regulated mechanisms. However, since MCF7-TAMR cells 
express higher levels of MKP-2 mRNA compared to parental MCF7 cells, this suggests 
that a more detailed analysis of MKP-2 promoter regulation is warranted.   Another  
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 Figure 19.  MKP-2 promoter driven luciferase activity.  A. Increasing amounts of the 
pGL3-MKP-2-pro construct were transfected into MDA-MB-231 cells to test construct 
activity.  4.0 x 10
5
 cells were plated in 6-well plates and luciferase activity was measured 
48 hr. post-transfection.  B. The pGL3-MKP-2-pro construct was transfected into MCF7 
cells to examine regulation of MKP-2 promoter following treatment with vehicle, 10 nM 
E2, 10 nM E2+1µM TAM, 1µM TAM, 10 nM E2+1µM ICI or 1 µM ICI.  2.5 x 10
5
 cells 
were plated in phenol red-free medium in 6-well plates.  Treatments were administered 
24 hrs post-transfection and luciferase activity was measured 48 hr. post-transfection.  
Results represent the average of three independent experiments.  Error bars represent the 
standard error of the mean.  C.  MCF7-TAMR cells were transfected with the pGL3-
MKP-2-pro construct and luciferase activity was measured as described in Panel B. 
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possible explanation for the observed accumulation of MKP-2 protein in MCF7-TAMR 
cells is its post-translational modification by ERK1/2 or another kinase.  As noted 
previously, MKP-2 protein can be phosphorylated by active ERK1/2, which stabilizes the 
protein.
19
  This phosphorylation is required to prevent rapid proteasomal degradation and 
to allow MKP-2 to carry out the dephosphorylation of MAPKs.
19
  Taking these results 
together, it is clear that further investigation is necessary to identify the mechanisms 
responsible for regulating MKP-2 in response to tamoxifen treatment.  
Conclusion 
 MKP-2, a nuclear MKP that preferentially activates ERK and JNK1/2 over 
p38,
11,75
 has been shown to be overexpressed in breast cancer tissues
24
, but no connection 
had been made previously between MKP-2 expression and its role in tamoxifen 
sensitivity.  The data presented here have shown that compared to parental MCF7 cells, 
MCF7-TAMR cells exhibit increased MKP-2 gene and protein expression and that MKP-
1 gene and protein expression are negligible.  MTT analysis revealed that MKP-2 
overexpression diminishes cell proliferation in response to estrogen compared to vector 
control cells, but that tamoxifen sensitivity was maintained.  MKP-2 expression was 
increased following tamoxifen treatment and a 1207 bp putative promoter was identified.  
Its regulation by E2 and anti-estrogens was examined in MCF7 and MCF7-TAMR cells.  
MKP-2 basal promoter activity was low and treatment with hormone had no influence on 
basal activity.  However, this 1207 bp fragment showed robust luciferase reporter activity 
in MDA-MB-231 cells.  These data suggest that elements regulating hormonal response 
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of MKP-2 probably lie outside the 1207 bp fragment used for the promoter assay or that 
MKP-2 gene expression is controlled by non-classical E2 responsive mechanisms.  
Taken together, the results presented in this chapter suggest that MKP-2 
overexpression sensitizes breast cancer cells to tamoxifen treatment and that tamoxifen 
resistant cells upregulate MKP-2 expression to potentially return them to a tamoxifen 
sensitive state.  In a proposed working model (Fig. 20), treatment of MCF7 cells with 
tamoxifen increases MKP-2, which dephosphorylates ERK1/2.  MCF7 cells are 
dependent on E2/ERα for activation of ERK1/2, which is inhibited by tamoxifen.  
Dephosphorylation of ERK1/2 by tamoxifen-induced MKP-2 slows cell proliferation and 
induces cell death.  In tamoxifen resistant MCF7 cells, phosphorylated ERK1/2 is present 
at high levels.  These cells are insensitive to E2 and ERK1/2 activation is driven by 
growth factor signaling pathways, such as EGFR and HER2, which are known to be 
overexpressed in tamoxifen resistant tumors.
36
  MKP-2 levels are upregulated in TAMR 
cells, but are unable to inhibit ERK1/2 activation probably because of robust activation of 
ERK1/2 by growth factor pathways.  Previous work in our lab has shown that activated 
ERK1/2 phosphorylates MKP-2 on Ser 386 and Ser 391, which stabilizes the MKP-2 
protein and protects it against proteasomal degradation without affecting its catalytic 
activity.
19
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Figure 20.  Working model depicting the role of MKP-2 in tamoxifen sensitivity.  In 
tamoxifen sensitive cells, phosphorylated ERK1/2 is present, indicating that cell-growth 
signaling pathways are activated.  Following treatment with anti-estrogens such as TAM, 
MKP-2 protein expression is increased, which leads to the dephosphorylation of active 
ERK1/2, slowing or eliminating cell proliferation.  In tamoxifen resistant cells, 
phosphorylated ERK1/2 is constitutively present at higher levels than in tamoxifen 
sensitive cells.  These cells are constantly upregulating MKP-2 protein expression in an 
attempt to return the level of active ERK1/2 to that of a tamoxifen sensitive cell.  
Continuous stimulation of ERK1/2 by growth factors, which are not sensitive to 
inhibition by tamoxifen, leads to the persistence of growth signals in the cell. 
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CHAPTER 4 
SUMMARY AND DISCUSSION OF CONCLUSIONS 
It is no secret that the emergence of resistance to currently available therapies is a 
major problem seen all too frequently in the clinical setting.  Research aimed at 
discovering the mechanisms underlying drug resistance and finding biomarkers that 
would be able to classify tumors as either drug resistant or drug sensitive has been a 
major focus of the field in recent years.  Cell signaling pathways have been central 
figures in many of these studies.  One such family of signaling pathways that has 
emerged as a player in breast cancer progression and resistance is the MAP Kinase 
family.   
 In mammalian cells, the MAPK family is made up of three branches: ERK, JNK 
and the p38 MAPKs.  These kinases are activated by a variety of cellular stimuli, 
including growth factors, cytokines and cellular stress.
2-6
  ERK1/2 in particular has been 
shown to have increased activity in breast tumors and to be connected to poor prognosis 
and endocrine therapy resistance in breast cancer patients.
23,32
  Subsequent research 
revealed that it was possible to pharmacologically inhibit ERK1/2 activity and restore 
TAM sensitivity.
38
  This begs the question: what role do MAP Kinase Phosphatases, the 
endogenous negative regulators of MAPKs, have in affecting the tamoxifen sensitivity of 
breast cancer cells? 
 The MKPs are a family of dual specificity phosphatases that attenuate the activity 
of the MAP Kinases by dephosphorylating the threonine and tyrosine residues found in a 
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TXY motif.
8
    MKP-1 and MKP-2 have shown the ability to dephosphorylate all three of 
the MAPKs, although MKP-1 prefers to act on JNK and p38 over ERK and MKP-2 acts 
primarily on ERK and JNK and not on p38.
10-12
  Both MKP-1 and MKP-2 are known to 
be overexpressed in breast cancer,
5,6,24
 but to date no connection between these proteins 
and breast cancer tamoxifen sensitivity has been established.  MKP-1 has been previously 
linked to chemotherapy resistance in a variety of cancer types, with its overexpression 
leading to a decrease in JNK activity, which contributes to decreased apoptosis in cancer 
cells.
6
  The hypothesis for this project, which states that an increase in MKP-1 protein 
expression would contribute to changes in tamoxifen sensitivity via the inhibition of 
JNK-mediated apoptosis, was based on this evidence.   
 In the research presented in this dissertation, the objectives were to: (a) 
characterize MKP-1 and MKP-2 expression in breast cancer cells to begin to dissect their 
contributions to tamoxifen sensitivity; (b)  investigate changes in MAP Kinase activation 
and correlate them to MKP expression in both tamoxifen sensitive and tamoxifen 
resistant cells in order to clarify the overall picture of MAPK signaling in tamoxifen 
sensitivity; and (c)  to examine the promoter sequence  of MKP-2 to provide insight into 
its regulation in breast cancer. 
 MKP-1 and MKP-2 expression were found to be low in MCF7 breast cancer cells, 
which are known to be tamoxifen sensitive.  MCF7 cell lines overexpressing MKP-1 or 
MKP-2 were generated and treated with E2, E2+TAM, TAM alone, E2+ICI or ICI alone 
and it was demonstrated that MKP-1 protein expression was not altered following these 
treatments, but that MKP-2 protein expression increased in response to treatment with 
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anti-estrogens.  Overexpressing MKP-1 decreased cell proliferation in response to E2 
treatment and did not change TAM sensitivity.  Western blot analysis also showed that 
MKP-1 activity was directed toward ERK1/2, not JNK1/2, as JNK1/2 phosphorylation 
was not observed in vector control cells.  MKP-1 overexpression eliminated ERK1/2 
phosphorylation compared to vector control cells.  These results taken together disproved 
the study hypothesis that MKP-1 contributes to changing tamoxifen sensitivity by 
inhibiting JNK1/2-mediated apoptosis.  However, the observation that MKP-2 protein 
expression was increased following TAM treatment provided an interesting new focus for 
this project.   
 Before beginning to study the effect of MKP-2 overexpression on tamoxifen 
sensitivity, MKP expression in MCF7 and MCF7-TAMR cells was characterized.  These 
experiments showed that MKP-2 protein was increased in MCF7 cells following anti-
estrogen treatment and constitutively expressed in MCF7-TAMR cells.  MKP-1 protein 
expression was not detected in either cell line.  MKP-2 mRNA was also shown to be 
increased in MCF7-TAMR cells, while MKP-1 mRNA was undetectable.  When MKP-2 
was overexpressed in MCF7 cells, MTT analysis revealed that, similar to MKP-1, it 
decreased cell proliferation in the presence of estrogen when compared to vehicle control 
cells.  MKP-2 overexpression cells were still sensitive to TAM treatment.  When MKP-1 
or MKP-2 protein was overexpressed in MCF7 cells and treated with E2 or the 
combination of E2 and one of three increasing concentrations of tamoxifen, MTT analysis 
showed that MKP-2 significantly decreased cell proliferation compared to vector control 
cells.  When compared to MKP-1 overexpression, MKP-2 significantly decreased cell 
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proliferation across all treatment conditions, suggesting that MKP-2 overexpression 
actually sensitizes cells to tamoxifen treatment.  Western blot analysis showed that MKP-
2 was able to eliminate ERK1/2 phosphorylation. 
 MCF7-TAMR cells exhibited a high level of ERK1/2 activation and constitutive 
expression of MKP-2 protein.  These two results seem at odds with each other given that 
MKP-2 overexpression seems to slow cell proliferation by dephosphorylating ERK1/2 
and that these cells were sensitive to tamoxifen treatment.  Previous work in our lab, 
however, has shown that activated ERK1/2 is able to phosphorylate MKP-2 on Ser 386 
and Ser 391, forming a feedback loop that stabilizes the protein and protects it from 
proteasomal degradation.
19
  The working model proposes that MCF7-TAMR cells may 
upregulate and stabilize MKP-2 protein in an attempt to return activated ERK1/2 to 
normal cellular levels.  Even when constitutively expressed, MKP-2 is unable to 
dephosphorylate all of the active ERK1/2 present in the tamoxifen resistant cells and the 
drug is rendered ineffective in halting cell proliferation. 
 Inhibiting Raf/MEK/ERK signaling has become an attractive therapeutic strategy 
in recent years and has been met with various degrees of success.  Many drugs have been 
developed to target EGFR activity, which is the head of the pathway, but complex 
signaling networks and crosstalk between pathways also necessitate the development of 
inhibitors to target downstream components of this signaling axis.  One class of agents 
particularly relevant to the studies presented here is MEK inhibitors.  While finding a 
good deal of preclinical success, only a handful of drugs have progressed beyond Phase I 
clinical trials, often due to poor pharmacologic profiles
81
 and toxicity.
82
  The results 
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presented here demonstrate that increasing MKP-2 expression in hormone-responsive 
MCF7 cells reduced ERK1/2 activity and increased their sensitivity to tamoxifen 
treatment.  While increasing the expression and activity of MKP-2 itself to sensitize cells 
to tamoxifen treatment is probably not a viable therapeutic strategy at this time, these 
results support the importance of continuing to develop clinically effective ways to 
reduce ERK1/2 activity in breast cancer cells.  The idea that MKP-2 plays a role in 
chemotherapy response is also supported by a recent study by Balko et al, in which 
molecular profiling of basal-like breast cancer tissues revealed that loss of MKP-2 
expression was associated with increased ERK1/2 pathway activation and reduced 
disease-free survival following neo-adjuvant chemotherapy.  The authors also suggest 
that MKP-2 expression could be used as a biomarker for MEK inhibitor sensitivity in 
these patients.
83
  In light of these results, MKP-2 might also be useful as a marker for 
sensitivity in tumors that are candidates for tamoxifen treatment, although further 
development of reagents that can specifically differentiate the activity and expression of 
MKP-2 from MKP-1 are necessary for this strategy to be effective. 
The regulation of MKP-2 gene expression in response to estrogen and tamoxifen 
treatment has proven to be complex and in need of further clarification.  MKP-2 promoter 
analysis revealed the presence of estrogen response element half-sites, as well as 
response elements for other transcription factors, such as AP-2, that are known to be 
regulated by estrogen signaling.  Measurement of MKP-2-driven luciferase reporter 
activity following treatment with estrogen, tamoxifen or ICI did not demonstrate any 
significant change compared to vehicle control treated cells in either MCF7 or MCF7-
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TAMR cells.  This suggests that further investigation is necessary to uncover the 
mechanisms responsible for regulating MKP-2 expression in response to tamoxifen 
treatment. 
The increased ERK signaling present in breast cancer and its connection to 
tamoxifen resistance has been well documented.  Much research has been done to try to 
discover underlying mechanisms responsible for this activation, but less attention has 
been paid to the molecules responsible for attenuating MAPK signaling, namely MKPs.  
The studies presented in this dissertation characterize for the first time the expression and 
activity of MKP-1 and MKP-2 in response to tamoxifen treatment and their effect on 
tamoxifen sensitivity.  While this is an important advance in the MAP Kinase 
Phosphatase field, further examination of the connection between MKP-2 and response to 
tamoxifen is necessary to determine how this knowledge might be translated into clinical 
benefit for breast cancer patients. 
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 The deregulation of cell signaling is a very important component in the 
development and progression of cancer.  One group of signaling molecules that has been 
implicated in these processes is the Mitogen-Activated Protein Kinase (MAPK) family 
which consists of three major branches in mammalian cells: ERK, JNK and p38.  The 
activity of these kinases has wide-ranging effects within the cell and must be tightly 
regulated.  This is partially accomplished through the activity of Mitogen-Activated 
Protein Kinase Phosphatases (MKPs).  The MKPs are a family of eleven dual-specificity 
threonine-tyrosine phosphatases that attenuate MAP Kinase signaling by 
dephosphorylating them.   
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 Increased ERK signaling has been shown to correlate with poor prognosis in 
breast cancer patients and is commonly found in tumors that are resistant to tamoxifen 
treatment.  JNK signaling has also been shown to be increased in breast cancer tissue 
samples.  MKP-1 overexpression in breast cancer has been connected with resistance to a 
number of different chemotherapeutic agents with the underlying mechanism being a 
decrease in JNK-mediated apoptosis, but no association with tamoxifen response has 
been previously studied.  These observations led to the hypothesis that MKP-1 
overexpression contributes to changes in tamoxifen sensitivity via the inhibition of JNK-
mediated apoptosis. 
 The characterization of MKP-1 following its overexpression in the MCF7 cell line 
revealed that its expression is not changed after tamoxifen treatment, but that the 
expression of MKP-2 was increased following treatment with anti-estrogens.  Both MKP-
1 and MKP-2 decreased cell proliferation in response to estrogen and maintained the 
tamoxifen sensitivity of MCF7 cells.  This decrease in proliferation was attributed to the 
elimination of ERK phosphorylation, as no JNK activation was observed in these cells.  
MKP-2 protein expression was shown to be constitutive in MCF7 tamoxifen resistant 
cells, while MKP-1 expression was not detected.  All of these results suggest that MKP-2 
expression is upregulated in response to tamoxifen treatment in order to dephosphorylate 
ERK and slow cell proliferation.  In tamoxifen resistant cells, upregulation of MKP-2 
expression is most likely an attempt to bring the high levels of ERK activation back down 
to a more normal level.  Its inability to do so is what allows the tamoxifen resistant 
phenotype to persist. 
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